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Deep vein thrombosis (DVT) is a common condition affecting 1-2% of the 
population. It can be further complicated by serious sequelae such as life 
threatening pulmonary embolus and the chronically debilitating post-thrombotic 
syndrome. The main treatment modalities available for DVT are only able to limit 
disease progression, with resolution occurring physiologically. Natural resolution of 
DVT occurs through a process of thrombus retraction and recanalisation which is 
comparable to progenitor mediated neovascularisation. The focus of this project 
was to examine the circulating progenitor cell response to venous thrombosis and 
to profile the underlying cytokine response. This data was ultimately used, to 
manipulate the number of circulating progenitor cells and expression of cytokines 
to enhance the recanalisation process. 
 
The presence of venous thrombus produced a bimodal circulating haematopoietic 
progenitor cell response whilst in the bone marrow compartment progenitor cells 
were simultaneously depleted. GCSF, GMCSF, VEGF, PlGF and SDF1 were 
expressed differentially in thrombus, vein wall and plasma, with the laparotomy 
wound mirroring the cytokine profile of the resolving thrombus. The expression 
pattern of PlGF in the resolving thrombus was however, unusually specific and not 




In order to enhance recanalisation two approaches were used. The first was 
peripheral upregulation of bone marrow mononuclear cells which localised to the 
thrombus vein wall interface and enhanced venous recanalisation 2-fold. Secondly 
adenoviral constructs were used to upregulate PlGF and SDF1 protein directly 
within the thrombus. Upregulation of both proteins enhanced thrombus 



















1.1 INTRODUCTION & CLINICAL OVERVIEW OF 
DEEP VEIN THROMBOSIS 
1.1.1 DEFINITION 
Deep vein thrombosis (DVT) is the formation of a semi-solid, structured obstructive 
lesion which develops in the deep veins of the lower limb (in vivo). This is distinct 
to a clot which is an amorphous structure of coagulated blood outside the vein (ex 
vivo).   
1.1.2 EPIDEMIOLOGY 
DVT is a common condition which can give rise to fatal pulmonary embolism and 
debilitating post-thrombotic syndrome (PTS)1. The annual incidence of DVT is 
about 5 per 10,000 as shown by a  recent meta-analysis of studies, which were 
carried out mainly in Sweden and the USA2. This analysis found that 2 per 10,000 
were idiopathic and 1-2 per 10,000 were complicated by a pulmonary embolus. 
More recently a UK primary care based study estimated the incidence to be 74.5 
per 100,000 patient years3.  The risk of DVT appears to rise exponentially with age, 
occurring rarely before the age of twenty, but rising significantly there after4.  
1.1.3 CLINICAL PRESENTATION 
DVT presents with calf pain and swelling, which is commonly unilateral. The 
differential diagnosis includes cellulitis, Baker’s cyst, muscular injury, tumour, 
infection, arterial aneurysm, and Achilles tendon inflammation or rupture5;6.  
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If thrombus is located in the proximal femoral or iliac veins then the leg swelling 
can be much more pronounced and may lead to one or both of the following: 
 
Phlegmasia Alba Dolens           (PAD)  
Phlegmasia Caerulea Dolens    (PCD) 
 
In PAD, thrombosis involves the major deep venous channels of the extremity only, 
sparing collateral veins and therefore allowing some venous flow. In PCD there is 
complete obstruction to venous flow from the limb which can result in venous 
gangrene if the increased pressure within the limb exceeds the local arterial 
pressure7.  
1.1.4 RISK FACTORS  
Various factors predispose to DVT and they can be divided into acute (transitory) 
and chronic (Table 1.1.1). These factors are important for risk stratification when 











Table 1.1.1 Risk factors for deep vein thrombosis  
(adapted from Rawat11) 
ACUTE CHRONIC 
Trauma  Age 
Immobilisation Obesity  
Surgery Malignancy 
Long distance travel (8hrs) Chemotherapy 
Intravascular device (i.e. central line) Oestrogen therapy 





Abnormalities of clotting factors can also predispose to DVT and they are known 
collectively as thrombophilias (Table 1.1.2). They include the Factor V Leiden gene 
mutation that confers a seven-fold increase in the incidence of DVT in 
heterozygotes and an 80-fold increase in homozygotes. The mutation is present in 
about 5-8% of the general population12. Others mutations include the prothrombin 
gene mutation (G20210A), anti-thrombin III deficiency, protein C and S deficiency, 
hyperhomocysteinuria and increments in certain clotting factors i.e. VIII, IX and 






Table 1.1.2 Inherited Thrombophilias14  
Thrombophilia Prevalence (European population) % 




Protein C deficiency 0.2-0.33 
Protein S deficiency unknown 
prothrombin (G20210A) gene 
mutation 
2 
Anti-thrombin deficiency 0.25-0.55 
Lupus anticoagulant 2 
Homocysteinaemia 11 
Dysfibrogenaemia 0.8  
Plasminogen deficiency 2-4 
 
1.1.5 DIAGNOSIS 
Clinical diagnosis of DVT is difficult, as calf pain and swelling are non-specific 
symptoms. Scoring systems can help to filter out those unlikely to have a DVT and 
avoid unnecessary imaging. Although several scoring systems have been 
developed6, the Well’s Criteria is the only one that has been widely accepted15. 
Below (Table 1.1.3) is an example of a modified Well’s Scoring Chart16, Well’s 
scoring has only been validated  in the hospital setting and is not necessarily 






Table 1.1.3 Modified Well’s scoring chart for DVT 
Clinical Feature Score 
Active cancer treatment within the last 6 months 
or palliative 
1 
Paralysis, paresis or plaster immobilisation of 
lower extremities 
1 
Bedridden for <3 days or major surgery within 12 
weeks requiring general/regional anaesthesia  
1 
Localized tenderness along distribution of the 
deep venous system 
1 
Swelling of entire leg 1 
Calf swelling >3 cm than asymptomatic leg at 
10cm below tibial tuberosity  
1 
Pitting oedema confined to the symptomatic leg 1 
Collateral superficial veins (non-varicose) 1 
Previously documented DVT 1 
Alternative diagnosis at least as likely as DVT                      -2 
 





During the 1990’s,  the addition of the D-dimer blood test increased the negative 
predictive value of the Well’s scoring system20. D-dimers are the breakdown 






Fig 1.1.1 Cross-linked fibrin broken down by plasmin to produce D-dimers22 
 
It is a highly sensitive (but non-specific) blood test that is used to exclude the 
diagnosis of DVT23. The test does however have certain limitations e.g. D-dimer 
levels increase during surgery, pregnancy, trauma, malignancy as well certain 
inflammatory conditions and  are therefore of limited use in these settings24;25. It is 
often used in conjunction with the Well’s score; a low pre-test probability with a 
negative D-dimer test, allows safe discharge without the need for ultrasound. In 
those with a high pre-test probability duplex ultrasonography is indicated 
regardless of the D-dimer score26. More recently the PROLONG and PROLONG II 
trials have demonstrated that the D-dimer test can be used to predict the risk of 
DVT recurrence and may also be useful in predicting treatment duration27;28. 
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1.1.6 IMAGING MODALITIES  
Several imaging modalities can be used to visualise DVT in the lower limb. 
Although duplex ultrasonography is regarded by most as the gold standard, the 
advantages and disadvantages of alternate modalities are discussed below: 
 
Duplex  
In the UK DVT is largely diagnosed on the basis of duplex scanning; a combination 
of ultrasound and Doppler which measures flow velocity29. Duplex ultrasonography 
has the advantage of being non-invasive with a sensitivity and specificity that 
exceeds 95% and 98% respectively for symptomatic proximal DVT i.e. above knee, 
this falls to 11-100% and 90-100% below the knee30. The disadvantage of 
ultrasound (US) is that it does not visualise the pelvic veins and is of limited value 
in those who are obese or in plaster cast immobilisation10. 
 
Venography  
Venography is still considered by a few to be the gold standard for calf vein (below 
knee) thrombosis31. Intravenous contrast is injected into the foot after which x-ray 
images are taken of the affected limb. It has been largely superseded by duplex, 
because it is an invasive and expensive procedure that is not widely available26. 
Computerised Tomographic (CT) venography is a variation on this same format 
and  is 100% sensitive and 96% specific32. Its greatest advantage over US 
scanning is that the patient’s body habitus is not a limitation and therefore the 
pelvic veins can also be visualised10.  
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Indirect CT venography is currently the diagnostic modality used for pulmonary 
embolism, its use in DVT however appears to be no more sensitive than dulpex33-
35.  
 
Magnetic Resonance Direct Thrombus Imaging (MRDTI) 
MRDTI uses the paramagnetic properties of methaemoglobin within thrombus to 
create a signal which is directly proportional to the amount of methaemoglobin 
present36;37. MRDTI does not require any contrast enhancement and has the 
added benefit that the peripheral and pulmonary veins within the thorax can be 
imaged simultaneously32.  Its sensitivity and specificity for below knee DVT is 92% 
and 94%36. A recent meta-analysis did not demonstrate superiority over duplex 
ultrasonography38 but there may be a role for evaluating pelvic veins, particularly in 
circumstances such as pregnancy where CT would be contraindicated39.  
1.1.7 MEDICAL MANAGEMENT  
Once a DVT has been diagnosed, management consists of limiting thrombus 
extension, recurrence, PE and long-term complications using a combination of 
anticoagulation, lower limb compression and in certain circumstances 
interventional procedures40-42. Over the last fifty year, anticoagulation has been 
achieved by the use of low molecular weight heparin and ultimately warfarin in the 
majority of patients43.  Unfortunately both the unfractionated form of heparin and 





THE ORIGINAL ANTICOAGULANTS: 
 
Unfractionated Heparin (UFH)  
Heparin was originally used only in its unfractionated form, its anticoagulant effect 
occurs by inactivating thrombin and activated factor X (factor Xa) through an 
antithrombin (AT)-dependent mechanism45. Patients have to remain hospitalised 
for heparin treatment because it is given intravenously and because of its narrow 
therapeutic window, which has to be regularly monitored using the activated 
thromboplastin time (APTT)46. 
 
Low Molecular Weight Heparin (LMWH) 
The development of Low Molecular Weight Heparins (LMWH) such as Enoxaparin 
have dramatically simplified the management of DVT. LMWHs can be administered 
subcutaneously allowing out-patient use and do not require monitoring47. Several 
studies comparing LMWH with UFH have shown that LMWHs are just as 
efficacious as their predecessor UFH46;48-50.  
 
Warfarin  
Warfarin is a synthetic derivative of coumarin; a chemical found naturally in certain 
plants45.  Most famously known as a rodenticide, it wasn’t until the 1940’s and 
1950’s that it was first used clinically45. Warfarin reduces blood coagulability by 
preventing the activation of vitamin K dependent clotting factors II, VII, IX and X. It 
is monitored using the International Normalised Ratio (INR) which is calculated 
based on the patients prothrombin time (PT)51.  
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The difficulties encountered in administering heparin and warfarin have lead to the 
development of several new therapies based upon the characteristics of the ideal 
anticoagulant (Table 1.1.4).   
 
Table 1.1.4 The ideal anticoagulant  
(adapted from Bounameux52) 
CHARACTERISTICS OF THE IDEAL ANTICOAGULANT  
Administered orally, one tablet daily 
Highly effective in reducing thromboembolic events 
Predictable dose response and kinetics 
Low rate of bleeding events 
Wide therapeutic window 
No dose adjustment required 
Little interaction with food or other drugs 
Low, nonspecific plasma protein binding 
Inhibition of both free and clot-bound activated coagulation factors 
 
 
Emerging therapies   
The new drugs are much more target specific and can be subdivided into classes 
according to the factors which they affect (Fig 1.1.2): 
 
(A) Specific inhibitors of factor Xa (Fondaparinux, Rivaroxaban) 



















Fig 1.1.2 Coagulation steps inhibited by developing anticoagulants 
 (Adapted from Bounameaux52) 
 
Inhibitors of Factor Xa 
Fondaparinux  
Fondaparinux is a selective inhibitor of Factor Xa. It is a subcutaneously 
administered pentasacchardie which binds to antithrombin and has a half life of 
17hrs53. It works by increasing the affinity of antithrombin for factor Xa thereby 














effective as LMWH, with the added advantage of not causing heparin induced 
thrombocytopenia, its use is currently limited by expense55.   
 
Rivaroxaban 
Rivaroxaban was the first orally administered factor Xa inhibitor with an 80% 
bioavailability 3hrs after administration. The RECORD 1-4 trials compared it to 
enoxaparin in the prevention of DVT and showed that Rivaroxban was significantly 
superiority to enoxparin in relation to the primary outcome i.e. total number of VTE 
with non-significant difference in major haemorrhagic complications56;57. NICE has 
since recommended Rivaroxban for the prophylaxis of DVT in major orthopaedic 
surgery. Early literature evaluating Rivaroxban in the treatment of DVT is also now 
emerging although it has yet to qualify as an alternative to low molecular weight 
heparin and warfarin 56.  
 
Direct Thrombin inhibitors  
Ximelagatran  
Ximelagatran is a prodrug of Melagatran which directly interacts with thrombin’s 
active site. It showed promise in several trials such as EXULT (North American 
VTE Prevention Trial)58, THRIVE (Trial Evaluated Ximelagatran for acute VTE)59 
and the SPORTIF (Non-inferiority trial against dose adjusted warfarin)60. The 
Federal Drug Agency in 2004 however, did not approve Ximelagatran for general 




Dabigatran etexilate  
Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is 
orally available as the prodrug, Dabigatran etexilate. It is the current favourite as a 
suitable replacement for warfarin with a half life of approximately 15hrs making it 
ideal for once daily dosing. It is renally metabolised and so far no evidence of 
hepatotoxicity has been documented. Trials such as RE-MODEL62, RE-NOVATE63 
and RE-MOBILIZE64 have all demonstrated non-inferiority to enoxaparin and 
further trials looking at secondary prevention of DVT are underway54.  
 
Non-pharmaceutical adjuncts  
Physical compression is used both in the prevention of DVT in hospitalised patients 
and also in the treatment for people who have had a DVT65. The two commonest 
methods used, are graded elastic compression stockings and intermittent 
pneumatic compression.  
 
Graduated compression stockings  
Graduated stockings produce a higher pressure at the level of the ankle than at 
points above the ankle. In this way blood flow is encouraged from back up the leg 
into the central circulation. Several mechanisms underpin stocking function: 
prevention of stasis, enhancing the calf muscle pump, improving venous valve 






Intermittent pneumatic compression (IPC) devices consist of an inflatable sleeve 
for the leg and an electrical pneumatic pump that fills it with compressed air. The 
sleeve cycles between inflation and deflation increasing blood flow through venous 
system by up to 200%, the shear effect of the increase in blood flow increases 
fibrinolytic activity68 as well as a rise in Tissue factor pathway inhibitor protein 
(TFPI) and a reduction of FVIIa67. Although it is accepted that compression 
stockings and pneumatic compression reduce the incidence of DVT, no clear 
difference between the two technologies has been identified69. 
1.1.8 INVASIVE THERAPIES FOR REMOVING THROMBUS  
Invasive management of DVT involves removing the thrombus either mechanically 
or chemically. Its indications are still limited to a select number of patients, usually 
those with occlusive iliofemoral DVT41. 
 
Percutaneous mechanical thrombectomy 
Percutaneous mechanical thrombectomy (PMT) has advanced considerably since 
its inception over fifty years ago, this has been facilitated by the embolectomy 
catheter developed by Fogarty70.  A catheter with an inflatable balloon is passed 
down the vein through the thrombus at which point the balloon is inflated and the 
catheter retrieved, bringing with it the thrombus. Maceration and fragmentation of 
the thrombus can occur and there is also the theoretical risk of valvular damage. It 
has been shown that long-term vein patency is improved by thrombectomy 
compared with anti-coagulation alone and leads to reduced venous 
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insufficiency71;72. Since its development there have been trials examining its effect 
in combination fibrinolytic agents which have proven superior to  PMT in isolation73.   
 
Pharmaco-mechanical thrombolysis  
Mechanical thrombectomy has now largely been superseded by pharmacological 
catheter directed venous thrombolysis (CDVT) which has improved patency rates 
compared with anti-coagulation alone74. This technique remains interventional in 
that a catheter has to be passed down into the thrombus using image guidance to 
allow localised delivery of the chemical agent. There are several types of 
commercially available catheter, each with its own potential advantages: 
 
Trellis 8 
The Trellis 8  incorporates both pharmacological and mechanical thrombolysis75. It 
uses two inflatable balloons to enclose the thrombus, the enclosed segment 
contains a wire which rotates at high speed to mechanically fragment the thrombus 
mass. This mechanical process is combined with thrombolytic drug infusion (Fig 




Fig 1.1.3 The Trellis 875 
 
Angiojet Power Pulse 
The Angiojet Power Pulse™ uses pressurised high velocity saline stream for 
thrombus dissolution at the catheter tip. Once in the pathway of the jets, thrombus 
is broken up into small particles, the jets also provide the driving force for 
evacuation of the thrombus debris through the catheter and associated tubing. As it 
does not use thrombolytic agents it is particularly useful when chemical 






Ekos Endowave  
The Ekos™ Endowave uses ultrasound (2MHz) in a process known as acoustic 
streaming to alter fibrin structure and increase the number of plasminogen receptor 
sites available for thrombolytic agents77;78. In trials of CDVT for iliofemoral DVT, the 
Ekos Endowave has achieved success rates of approximately 80% in reducing 
thrombus load to at least 50% of pre-treatment size79;80. Complications included 
significant bleeding in up to 10% of patients, intracranial haemorrhage however, 
occurred in less than 1% of patients79;80.  
1.1.9 POST THROMBOTIC SYNDROME: THE CASE FOR ENHANCING 
THROMBUS RESOLUTION 
Post thrombotic syndrome (PTS) encompasses a wide spectrum of signs and 
symptoms which develop in chronic manner following  DVT (Table 1.1.5) 81.  
 
Table 1.1.5 Features of PTS  




Swelling Venous Ectasia 
Itching Hyperpigmentation 
Cramps Dependent cyanosis 
Paraesthesia Lipodermatosclerosis 





Epidemiology of PTS 
The incidence of PTS has been reported be as high as 50%, with significant 
morbidity occurring in 5-10% of patients82-84. In most cases PTS develops within 
2yrs of the primary DVT85. The condition remains underreported, because of a lack 
of consistency in how it is defined86.  It is estimated that more than one quarter of 
the 170000 new cases of venous stasis syndrome per year represent PTS87. The 
socioeconomic cost of this has been estimated by a Swedish study to be £3000 
per incident, or approximately 75% the cost of treating the primary DVT88.  
 
Pathophysiology of PTS 
It is thought that DVT results in ambulatory venous hypertension through a 
combination of venous obstruction and valvular dysfunction. The development of 
PTS appears to be multi-factorial, but some clinical studies have suggested that 
persistent and more proximal venous obstruction results in distal valvular 
incompetence and more severe PTS89-92. In canine models thrombolysis resulting 
in early resolution preserves both endothelial function and valve integrity compared 
with placebo93. It follows therefore that early removal of obstructing thrombus using 
interventional means may reduce long-term morbidity. Several prospective cohort 
studies have shown CDVT to be a safe and effective method of removing thrombus 
burden93;94. The CaVenT and ATTRACT studies are international multicenter 
studies comparing CDVT with anticoagulation95;96.  Initial results have shown 
increased early vein patency with CDVT, it is not known however, if this will 
translate into long-term benefits95-97. 
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Management of PTS 
Compression therapy is currently the main treatment strategy for managing PTS. 
Stockings have proved beneficial in reducing the impact of PTS98 and at the 
seventh American College of Chest Physicians conference, it was suggested that 
stockings should be used for at least 2 years following a DVT (2004)99. 
Compression strength and stocking length have not been clarified, although the 
below knee stocking appears far more acceptable to patients than the above knee. 
The evidence supporting pneumatic compression pumps is limited, however their 
use is restricted by impracticality for the wearer100. The Venowave (a light weight 
calf compression device) has been tested in a trial in patients with severe PTS 
based on the Villalta scale101 and has shown some promise in reducing PTS 
scores at the end of an eight week trial period when compared with compression 
stockings102.  
 
There is also emerging evidence that venoactive therapies such as aescin and 
rutosides give some symptomatic relief103. Horse chestnut seed extract (aescin) 
was shown in a Cochrane review to be effective for treating PTS symptoms with 
minimal adverse effects reported104.  Therapies such as this require more robust 






1.2 MECHANISM OF VENOUS THROMBUS FORMATION 
1.2.1 HISTORICAL OVERVIEW 
The first documented report of DVT came from Wiseman105 in 1676 when he noted 
that following a difficult labour, his patient  developed a swollen leg, he was the first 
to consider that the underlying cause was an abnormality in the circulation. In 
1846, Hewson106 hypothesised that venous thrombosis was caused by obstruction 
of veins by blood clots, with venous pooling playing a major role in this process. 
Interestingly Hewson106 also believed that thrombus formation was triggered by 
lymph within the plasma; this substance was later renamed fibrinogen.  
 
The most noteworthy understanding of DVT came from Virchow107 and 
Rokitansky108 although the latter is less well known. The triad of vessel wall 
(endothelial injury), venous stasis and hypercoagulability still remain 
fundamental to the understanding of venous thrombogenesis. It was noticed 
initially in conditions which leant themselves to elements of the triad i.e. in the later 
stages of pregnancy venous stasis was caused by immobility often in the form of 
bed rest. In addition pelvic vein trauma, caused by manipulation of the uterus, put 
patients at the highest risk of DVT immediately following delivery109. An 
increasingly elderly population has changed the demographics of those affected by 
DVT. In patients undergoing hip replacement without any form of prophylaxis, the 
incidence of DVT has been reported as high as 50%110, this in turn has renewed 




Virchow’s Triad Explored 
A venous thrombus consists of a laminar structure formed from layers of platelets, 
leucocytes and fibrin112. The laminar thrombus is structurally very different from 
what we consider a ‘clot’ which forms ex vivo or on circulatory arrest112. Virchow’s 
triad categorises the different elements contributing to the formation of DVT as 
listed below: 113;114 
   
  Vessel wall 
  Blood flow 
  Blood constituents 
 
The role of each of these elements has been explored through a combination of 
work in humans and animal models112;115-121.  
1.2.2 VESSEL WALL / ENDOTHELIUM 
Sevitt’s post-mortem work suggested that venous thrombi arise in both the valve 






Fig 1.2.1 The propagation of deep vein thrombi from a nidus in a valve pocket 
(A-C) and the deposition of successive layers of fibrin, platelets etc in a valve 
pocket, (D) retrograde thrombus propagation occurs when there is proximal venous 
obstruction (Reproduced from Sevitt123) 
 
The exact mechanism behind Sevitt’s theory was unknown, but he hypothesised 
that a nidus consisting of red and white cells was held together by platelet 
strands124. The role of endothelial injury was also unclear as the majority of thrombi 
studied by Sevitt, were lying over macroscopically intact endothelium123;124. More 
recently examination of autopsy specimens of iliofemoral veins in patients who 
succumbed to VTE, revealed that Von Williebrand Factor (vWF); a haemostatic 
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glycoprotein was consistently present, in the same study anti-vWF antibody 
resulted in a reduction in thrombus burden in a rabbit model125. VWFs function in 
venous thrombosis appears to be distinct to its role in platelet adhesion and 
aggregation126,  a reduction in platelet number or inhibition of aggregation does not 
appear to influence thrombus formation127-129. This substantiates the fact that 
venous thrombi are relatively platelet independent  in contrast to platelet rich 
arterial thrombi116.  
 
The endothelial lining of the vessel wall has several roles but most crucially, it 
maintains the balance between blood flow, fluidity and thrombus formation. Table 
1.2.1 lists both the anti-thrombogenic and pro-thrombotic factors associated with 
the endothelium130;131. Procoagulant factors are released during periods of 
endothelial disturbance initiating the inflammatory phase of thrombogenesis130;131 . 
Animal models have been used to shed further light on the role of endothelium in 
thrombogenesis132-134. In a rabbit model of jugular vein thrombosis, isolated venous 
injury did not result in thrombus formation, however both platelets and leukocytes 
adhered to the site of injury, with leukocyte migration occurring through the vessel 
wall when a short period of stasis was also induced135. Endothelial injury combined 
with prolonged stasis however resulted in thrombus formation in 90% of test 
animals136 suggesting that thrombus formation requires more than just vessel wall 






Table 1.2.1 Anti-thrombogenic and Procoagulant factors in the vein wall  
(adapted from Becker130) 
Anti-thrombogenic factors Procoagulant factors 
Thrombomodulin Platelet activating factor (PAF) 
Heparin, dermatan sulfate Endothelin-1 
tPA and uPA vWF (Von Willie Brand Factor) 
Nitric oxide Tissue factor 
Prostacyclin Plasminogen activator inhibitor 
(PAI)-I 
Interleukin 10 Factor V 
- Adhesion molecules: P-selectin, E-
selectin 
 
tPA-tissue plasminogen activator, uPA urokinase plasminogen activator 
1.2.3 BLOOD FLOW 
Analysis of flow patterns behind venous valves in canine long saphenous veins has 
shown that under physiological conditions, cells continually entered venous valve 
pockets and created vortices140. Red cell aggregates formed within these vortices 
subsequently dissolving as the vortex blood re-entered luminal flow140. The partial 
pressure of oxygen rapidly decreased within valve pockets, causing a relative 
hypoxia during low flow states, that occur during periods of immobility141. Once flow 
was made pulsatile however (mimicking normal calf puamp activity), oxygen levels 
within the valve pockets returned to that of the lumen141. Thrombus formation has 
been found in valve cusps as early as 2hrs after  non-pulsatile flow 141. This is 
consistent with data from  gamma imaging studies which used radioactively 
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labelled fibrinogen to show that thrombus formation in limb veins occurred 2-4hrs 
after the beginning of surgery142. This has resulted in the use of intraoperative  
Flowtron™ stockings, which encourage lower limb venous return through 
pneumatic compression in bed bound surgical patients to reduce thrombotic 
events143. Pneumatic compression was thought to be effective by increasing lower 
limb blood flow but work by Giddings et al.144 has shown that it also positively 
affects systemic haemostasis by increasing tissue factor pathway inhibitor (TFPI) 
and urokinase-type plasminogen activator (uPA) activity reducing the likelihood 
thrombus formation144. TFPI is the only known serine protease inhibitor  of the 
tissue factor (TF) protein a key element of the extrinsic pathway145.  Upregulation 
of TFPI attenuates thrombosis in animal models146;147. 
 
Hypoxia within valve pockets may stimulate thrombus formation by increasing the 
expression of the adhesion molecule P-selectin on the surface of endothelial 
cells148. P-Selectin and vWF are stored in secretary vesicles known as Weibel-
palade bodies within endothelial cells149, their  translocation to the cell surface 
leads to platelet and leucocyte adhesion to the endothelium150;151. P-selectin 
inhibition in a primate model of thrombosis resulted in diminished thrombus 
formation152;153. Its receptor P-selectin glycoprotein ligand 1 (PSGL-1) is found both 
on leucocytes and platelets as well as their respective microparticles154. 
Microparticles (MPs) are small phospholipid vesicles that are released from the 
surface of certain cells (platelets, leucocytes and endothelial cells). Once thought 
to occur only in disease states, they are now believed to occur physiologically154. 
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Thrombin and hypoxia amongst other mediators are thought to trigger their 
release, the evidence for this however, remains sparse155. MPs containing TF have 
been shown to accumulate at sites of venous stasis and thrombus formation in a P-
selectin dependent fashion156.  The role of MPs in thrombosis is likely to be 
mechanism dependent, i.e. if there is significant vascular trauma exposing  vein 
wall TF then thrombosis here is likely to be MP independent, at least in the first 
instance157.  
1.2.4 BLOOD CONSTITUENTS 
Haemostasis was historically described as a cascade or a waterfall model involving 
various clotting factors as part of the extrinsic or intrinsic pathways158 . This model 
highlights the interactions of the pro-coagulant proteins as a series of lytic 
reactions culminating in a common final pathway which results in the formation of 
fibrin (Fig 1.2.2)158.  It also identified that the anionic phospholipid surface provided 
by platelets or the injured vessel wall was essential for optimal function of the 
cascade. The artificial separation into separate pathways and the absence of 
cellular elements from the cascade has limited its application to in vivo 






Fig 1.2.2 Cascade model of coagulation 
(adapted from Hoffman158) 
 
In the last decade the cell based model (Fig 1.2.3) of coagulation has been 
accepted as a much more comprehensive view of intravascular haemostasis. It can 
be divided into three overlapping phases: 
 
Initiation 
TF was previously known as the initiator of the extrinsic pathway in the clotting 
cascade but it is now generally accepted that TF initiates in vivo coagulation. It has 
both sub-endothelial and circulating isoforms and is expressed on several cell 
types, including stromal fibroblasts, endothelial cells, platelets and leukocytes147. 
Recently evidence has also been found of the existence of TF in MPs as 
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mentioned above159. Exposed TF (vein wall and MP derived) activates FVII, the 
TF/FVII complex then activates FX and FIX, FXa then activates FV160. Any cell 
surface bound FXa and FV convert a small amount of the zymogen; prothrombin to 
thrombin.   
 
Amplification 
The small amount of thrombin generated on TF exposed cells then fully activate 
platelets through protease-activated receptors (PARs): PAR1 and PAR4 and also 
factors V, VIII and XI161.  
 
Propagation 
This occurs at the platelet surface which coordinates the assembly of  the tenase 
complex (FVIIIa/ FIXa), this activates FX which then complexes with FV to form the 
prothrombinase complex producing a burst of thrombin which converts soluble 
























Fig 1.2.3 Cellular model of the clotting cascade  
(adapted from Hoffman162) 
 
Termination of thrombosis 
Activated protein C (APC) terminates the haemostatic cascade by proteolytically 
cleaving and inactivating Va and VIIIa. This pathway is activated by proteolytic 
cleavage of protein C by thrombin. This reaction is catalysed by both 
thrombomodulin (TM) and the endothelial protein C receptor (EPCR) (Fig 1.2.4). 
The primary objective of this system is to confine thrombin formation to the area of 
injury. A safety mechanism which prevents widespread thrombogenesis includes 




























Fig 1.2.4 Termination of haemostatic mechanism  
















1.3 VENOUS THROMBUS RESOLUTION 
1.3.1 ORGANISATION 
Natural thrombus resolution occurs through a process of organisation that is 
accompanied by the recruitment of a variety of cells, into the thrombus (Fig 1.3.1).  
This includes neutrophils, monocytes, myofibroblasts, endothelial cells and their 
progenitors, from the vessel wall and the circulation120;163-167. This influx of cells 
facilitates the organisation and resolution of the thrombus in a process reminiscent 












  Fig 1.3.1 Histological section of a resolving human thrombus 
Dense cell infiltrate (dark nuclei), deposition of collagen 
(bright blue) and formation of recanalising channels in the 









Early inflammatory phase  
An acute inflammatory response results in early thrombus amplification and 
organisation157. The early phase of thrombus resolution is associated with a 
neutrophil influx, neutrophils are  polymorphonuclear (PMN) cells sometimes 
referred to as granulocytic because they contain small packages of preformed 
proteins171;172. They have a fairly short half life of 7-12hrs which is modulated by 
the presence of infection or inflammation172. Mature neutrophils are terminally 
differentiated cells that develop from CD34+ bone marrow precursors under the 
influence of various cytokines: interleukin-3 (IL-3), granulocyte-CSF (G-CSF) and 
granulocyte macrophage-CSF (GM-CSF)173. Many of these cytokines continue to 
influence neutrophil activity outside the bone marrow174.  
 
Previously an artificial model of thrombosis using stasis (The Chandler Loop) 
showed that PMN dependent uPA was responsible for resolution175. Subsequently 
in a rat model of thrombosis neutropenia resulted in a 60% increase in overall 
thrombus size, increased vein wall stiffness and fibrotic changes176. There was 
also a neutrophil dependent reduction in uPA which was two-fold lower in 
neutropenic animals177. This was associated with changes in local matrix 
metalloproteinases (MMPs), most noticeably a reduction in thrombus MMP9 levels 






Late inflammatory phase 
Monocytes are a large heterogeneous population of circulating leucocytes of 
myeloid lineage. They were once thought to be merely a precursor cell to 
macrophages, but over the last decade it has come to light that they in themselves 
have both inflammatory and anti-inflammatory roles178 . Monocytes express a large 
variety of inflammatory mediators and growth factors that are known to orchestrate 
tissue remodeling165;179. They are recruited into the thrombus with a characteristic 
temporal and spatial pattern, peaking at day 8 after thrombosis119;180. Monocyte 
chemoattractant protein 1 (MCP-1) is the primary orchestrator of monocyte 
chemotaxis and activation, its upregulation enhances thrombus resolution179. 
Thrombus resolution is impaired in CCR-2 (MCP-1 receptor) knockout models, but 
not in MCP-1 knockout animals. This suggests that there are likely to be other 
MCP subtypes181. MCP-1 also appears to effect thrombus resolution independent 
of its effect on monocytes179. 
1.3.2 FIBRINOLYSIS 
Several proteins are involved in controlling the ultimate dissolution of the thrombus.  
Plasmin is a key protein in fibrinolysis, plasminogen (its non-active form) binds to 
lysine and arginine residues on fibrin through secondary structural motifs known as 
kringles182. Plasminogen activators, uPA and tPA (serine proteases) activate 
plasminogen and are therefore important mediators of fibrinolysis and cell 
migration183;184. Plasminogen activator inhibitor 1 (PAI -1) secreted from both liver 
and endothelial cells is their primary inhibitor185. PAI-1 deficiency in mice makes 
them highly resistant to thrombosis186.  
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This has made the inhibition of PAI-1 increasingly attractive as an alternate 
therapeutic option to treat DVT186. Plasminogen activators are well recognised for 
their effectiveness in the lysis of coronary artery thrombi187;188. Work in mouse 
knockout models has shown that thrombus resolution is diminished in uPA 
deficient but not tPA deficient animals189. Rescuing the uPA-/- phenotype with wild-
type bone marrow transplant rescues normal thrombus resolution189.  This is in 
keeping with the theory that bone marrow (BM) plays an important role in thrombus 
resolution. 
1.3.3 VEIN WALL REMODELLING  
Vein wall remodeling occurs during the inflammatory response that ensues after 
thrombus formation186;190. The early invasion by PMNs is essential for fibrinolysis 
and collagenolysis157, and crucially they must be present early during thrombus 
resolution176. The occurrence of elastinolysis within the vein wall, results in wall 
stiffening and correlates with elevated levels of MMP2 and MMP9 as well as well 
as collagen I and III gene expression157. The thrombosis related vein wall injury 
results in elevated levels of profibrotic mediators such transforming growth factor β, 
IL-3 and and MCP-1191. Although MCP-1 is known to mediate resolution, it also 
appears to correlate with vein wall stiffness192. The inflammatory changes within 
the vein wall respond to treatment with LMWH or oral P-selectin,  reducing both 
vein wall stiffness and thickness192. MMP9 levels are raised following venous 
thrombosis, gene deletion studies have however, shown that it is not essential for 




1.4 THE ROLE OF PROGENITOR CELLS IN THROMBUS 
RESOLUTION   
1.4.1 POST-NATAL PROGENITOR CELLS 
The concept that as fully developed adults we can produce cells capable of 
endothelial regeneration has been a revolution in the world of vascular biology194-
201. Early evidence for post-natal vasculogenesis came from patients who 
underwent bone marrow or peripheral stem cell transplantation and subsequently 
developed a chimeric endothelial lining to their vasculature202.  This pointed to the 
post-natal existence of circulating PCs. Indirect evidence has come from studies 
correlating a reduction in putative PCs with increased atherosclerotic morbidity and 
cardiovascular risk203;204.  There has been a large amount of work looking at the 
characterisation, function and role of these cells in the neovascularisation within 
the context of tumorogenesis, coronary artery disease and peripheral vascular 
disease200;205-214. It has been suggested that by manipulating PCs, it may be 
possible to accelerate wound healing, tissue regeneration and new vessel 
formation215. Thrombus resolution is an active and organised process which 
involves clot retraction and formation of endothelial lined bypass channels within 
the body of the thrombus. In human and rat thrombi, vascular channels form early 
in the resolution process and stain with the endothelial cell markers CD31 and 







  Fig 1.4.1 Recanalisation in human and murine thrombus 
  (A) VCAM-1 staining (B) CD31 staining channels formed within  
  thrombi (C) H&E stain of rat thrombus at 2 weeks (D) MSB stain of 4 
  week  thrombus showing residual vein wall thickening (adapted from 
  Moderai120) 
 
 
In an elegant study Moderai et al.209 demonstrated a temporal pattern in the influx 
of bone marrow derived progenitor cells into the resolving mouse thrombus209. 
They subsequently went onto to demonstrate that adenoviral upregulation of intra-
thrombus vascular endothelial growth factor (VEGF) enhanced thrombus resolution 





Human PCs peripherally injected into nude rats following thrombus formation has 
demonstrated enhanced recanalisation and increased blood flow when compared 
with controls animals217. Much like thrombus formation, resolution appears to be a 
highly organized process, involving both clot retraction and new vessel formation 




           Fig 1.4.2 New vessel formation in rat thrombus 
Cross section through rat thrombus showing a vessel 
Growing into the (T) thrombus mass from the (V) vein wall 








New vessel formation occurs through two processes: angiogenesis and 
vasculogenesis, which may be PC dependent.  
 
Angiogenesis is the sprouting of blood vessels from pre-existing vascular 
structures and occurs during normal physiological and pathological processes219.  
 
Vasculogenesis is the formation of blood vessels de novo from precursor or 
progenitor cells194. This process was thought only to occur in the prenatal period 
until Asahara et al.220   first demonstrated that PCs persisted into adult life.  
1.4.2 HAEMATOPOETIC PROGENITOR CELL CHARACTERISATION 
Although there is no agreement as to what objectively defines a PC in terms of its 
biology221, theoretically these cells are likely to reside within the bone marrow (BM) 
and are capable of self-renewal and regneration222. The BM is a source of both 
mesenchymal and HPCs, (Fig 1.4.3). HPCs are known to give rise to red cells, 
leucocytes, endothelial cells and platelets223. HPCs are capable off reconstituting 
the haematopoietic system of lethally irradiated mice after transplantation of even a 
single HPC224. Current evidence suggests that HPCs indirectly promote 
neovascularisation but are unlikely to be the precursors of post-natal endothelial 


















Fig 1.4.3 HPC development from bone marrow progenitor cells 
 
The practical characterisation of PCs particularly HPCs remains controversial 
partly because of the array of techniques used for their identification206;226. Cell 
culture techniques and flow cytometric analysis of peripheral blood have formed 
the basis of a number of PC related papers195;198;202;209;214. In order to better 
comprehend what we know about PCs, it is first necessary to understand how both 
of these techniques have been developed over the last ten years. 
 
Cell culture and colony forming units (CFUs) 
Culture of peripheral blood mononuclear cells has produced spindle like cells with 
an endothelial morphology227. These cells can be labelled with VEGFR2 (vascular 














endothelium) and VE-Cadherin (endothelial specific cadherin)198. They also 
positively stain with Lectin Europeaus Agglutinin-1 (UEA-1) and acetylated Low 
Density Lipoprotein (AcLDL). Under certain culture conditions these cells form 
colonies i.e. clusters of cells with rounder central cells and spindle like cells at their 
periphery, also known as colony forming units (CFUs) which have been used as a 
surrogate marker of PC number and function228-230.  
 
Several methods have since been used to grow CFUs from peripheral blood231. 
Characterisation of the cultured cells has revealed that only the method used by 
Lin232  gives  rise to colonies containing cells with a high proliferative capacity. 
These cells are known as late colonies, because of their  latent formation when 
compared to early colonies generated by the Hill 231 or Ito228 methods (Table 
1.4.1). The method used by Hill et al.231  gained popularity because of its  inverse 












Table 1.4.1 Differences in Early and Late Colony Forming Units 
 ALDH-aldehyde dehydrogenase, UEA-1 Ulex erupeaus agglutinin-1, acLDL-
acetylated low density lipoprotein, eNOS-endothelial nitric oxide synthase 
(adapted from Yoder233) 




Passage ability No Yes 
In vitro tube 
formation 
Partial Yes 
De novo vessel 
formation 
no Yes 















 CD133+ CD133- 
 VEGFR2+ VEGFR2+ 
 CD45+/- CD45- 
 CD14+/- CD14- 
 CD115+ CD115- 
 CD31+ CD31+ 
 ALDH bright ALDH bright/lo 
 acLDL uptake acLDL uptake 
 UEA-1 lectin binding UEA-1 lectin binding 
 eNOS+ eNOS+ 
 Von williebrand + Von williebrand + 
 




The validity of CFU staining with UEA-1 and AcLDL has recently been questioned 
as UEA-1 recognises the L-fucosylated molecules on the cell surface of endothelial 
cells, and this molecule has now been found on epithelial cells and platelets234;235 . 
It has been suggested that CFU cultures are being contaminated by platelets which 
form microparticles that fuse with and contribute to the cell surface markers of 
CFUs, allowing them to bind UEA-1236. Analysis of CFU mRNA also corroborates 
this finding as it shows that these cells do not contain the necessary mRNA for the 
proteins expressed on their cell surface236. Secondly AcLDL is taken up by 
monocytes as well as endothelial cells, proteomic comparison of monocytes and 
putative EPCs has shown an almost 80% congruency and although this means 
they are not identical it suggests that differentiating between them using UEA-1 
and AcLDL is likely to be flawed237;238.  
 
Flow cytometry 
Flow cytometry is used to identify cells based on the expression of cell surface and 
intracellular markers. Its strength rests in the ability to analyse large numbers of 
cells rapidly and efficiently. Using two or three cell markers to adequately identify 
PCs is a limited method for identifying a cell with a complex phenotype, but has 
been the preferred method for analysing these cells in fresh blood samples239. 
There are numerous antigens which have been used to identify PCs both by their 





Table 1.4.2 Endothelial progenitor cell markers used to identify EPC 
HSC-Haematopoetic stem cell, MSC-Mesenchymal stem cell, EPC-Endothelial 
progenitor cell 
Marker Expressed 
CD133 (AC133)240 HSCs, EPCs , neural and glial stem 
cells 
Sca-1 (Stem cell antigen 1)241 Early stem cell 
CD34220 MSCs, HSCs, EPCs 
VEGFR2  (Vascular endothelial 
growth factor receptor 2)220 
EPCs,  mature endothelial cells 
CD31 (PECAM-1: Platelet/endothelial 
cell adhesion molecule 1)242 
Platelets, EPCs, macrophages 
Von Williebrand factor243 Endothelial cells, Weibel Palade 
bodies, megakaryocytes 




The original combination of CD34 and VEGFR2 used by Asahara220 to characterise 
the putative endothelial progenitor cell initially gained popularity as these cells were 
incorporated into the vasculature of ischaemic rabbit hind limbs in a manner 
consistent with them becoming ECs220. It is now known however that mature ECs 
also express CD34 and VEGFR2244  and in order to exclude them a third antigen 
denoting a more immature cell type i.e. CD133 (human), Promonin-1(mice) or Sca-
1(mice), which are not found on mature endothelial cells have been used in 
combination with CD34 and VEGFR2245.  Despite the extensive literature using 
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only two of CD34, CD133 or VEGFR2221;246-249, triple positive 
CD133+CD34+VEGFR2+ cells are still considered by many to represent the gold 
standard progenitor cell with an endothelial phenotype227.  These cells however do 
not form tubular structures in either in vitro studies nor do they participate in the 
formation vasculature channels in vivo making them more likely to be HPCs244;250. 
This has lead to the conclusion that these cells are effecting change through the 
paracrine production of cytokines and not by lining newly formed vascular channels 
251. A lack of consensus regarding what defines EPCs and HPCs has made the 
study of this area increasingly difficult.   
 
1.4.3 REGULATION OF BONE MARROW MOBILISATION AND RECRUITMENT 
Since the discovery of circulating progenitors by Asahara252, a large number of 
chemokines have been implicated in progenitor mobilisation and recruitment 












Table 1.4.3 Factors responsible for progenitor mobilisation 
Factors influencing 


















Stromal derived growth 
factor 
CXCR4 Stem cell mobilisation 







Reduction of SDF-1 in 
bone marrow and 
increased CXCR4255  
GMCSF 
Granulocyte-Macrophage 
Colony Stimulating Factor 
GMCSF receptor + others  Stem cell mobilisation into 
circulation + homing to 
sites of ischaemia256 
Epo 
Erythropoietin 





Tie-2 , alpha(5)beta(1), 
alpha(v)beta(5) integrins 
Embryonic vascular 
development and tumor 
angiogenesis258 
SCF 
Stem cell factor 




CCR-2 Tumor angiogenesis260 
MMP-2, MMP-9 Metalloproteinase 
receptor (TIMP) 
Increase vascular 
permeability for stem cell 
migration261 
Statins ? VEGFR-2 VEGF mediated stem cell  
mobilisation262 
Exercise Unknown mechanism Increases circulating 







It is almost certainly the intricate interaction of several factors which results in PC 
mobilisation into the circulation and recruitment to areas of injury and 
hypoxia249;264;265. The cytokines measured during thrombus resolution in this study 
are reviewed in greater detail below: 
 
Granulocyte colony stimulating factor (GCSF) 
GCSF is a 25 kDa glycoprotein secreted by monocytes, macrophages, and 
neutrophils after cellular activation. It is also produced by stromal cells, fibroblasts 
and endothelial cells266. The GCSF receptor CD114 is expressed on all cells of 
granulocytic lineage as well as being expressed on placental, endothelial, cardiac 
myocytes and some tumor cell lines267. It has been used successfully in the clinical 
setting as Filgrastim to treat neutropenia, as well as prior to bone marrow 
transplantation to induce the release of bone marrow stem cells (BMSCs) into the 
circulation267. The realisation that it was produced by infarcted myocardium268 
resulted in animal studies in which GCSF administration resulted in mobilisation of 
BMSCs to the infracted heart in parallel with improved cardiac function269-271. This 
lead to several randomised control trials which sadly weren’t able to produce the 






Table 1.4.4 Trials assessing benefit of GCSF after myocardial infarction 




Stem Cells in Myocardial Infarction 
(STEMI)273 
No improvement, no obvious adverse 
effects 
Reinfusion of Enriched Progenitor Cells 
And Infarct Remodelling in Acute 
Myocardial Infarction (REPAIR-AMI)274 
Moderate improvement in ejection 
fraction 
Front-Integrated Revascularisation and 
Stem Cell Liberation In Evolving Acute 
Myocardial Infarction by Use of GCSF 
(FIRSTLINE-AMI)275 
Improved LV wall thickening and wall 
motion in infarction zone with 
dobutamine stress 
Regenerate Vital Myocardium by 
Vigorous Activation of Bone Marrow 
Stem Cells (REVIVAL -2)276 
No difference in LV function 
 
We now know that GCSF also has stem cell independent cardio-protective 
effects268. GCSF also appears to mobilise bone marrow CXCR4 through 
upregulation of stromal derived factor 1 (SDF-1) and matrix metalloproteinase 1 
(MMP-1)277. In a mouse model of thrombosis, the expression of circulating CCR2 
mRNA (the MCP1 receptor) increased following subcutaneous injection of 
recombinant GCSF278. GCSF injection resulted in greater macrophage ingress into 
the thrombus and enhanced resolution and organisation characteristics compared 
with the sham control278. The mechanisms by which GCSF produces its effects still 
require further investigation before we embark on further clinical trials. Studies with 
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animal models use otherwise healthy young animals and do not always translate 
clinically as trial patients are generally from an aged population resulting in a varied 
progenitor cell response to GCSF272;279. A study in rabbits examined this age 
related phenomenon and found that GCSF lost its efficacy in infarction remodeling 
in older animals280. Whilst we are continually advancing our knowledge of GCSF, it 
is not yet clear as to whether it will be useful as a mobilising agent for HPCs272. 
Granulocyte macrophage colony stimulating factor (GMCSF) 
GMSCF is a 25 kda protein in its glycosylated form and like GCSF it is best known 
for its use in bone marrow transplantation256. Under the influence of various 
interleukins and tumor necrosis factor (TNF) it can be secreted from several cell 
types including fibroblasts, chrondrocytes, smooth muscle, endothelial cells and 
inflammatory cells281. GMCSF mobilises neutrophils as well as cells of a 
macrophage lineage via the CD116 receptor256.  Systemic administration of 
GMCSF mobilises progenitors from the BM compartment into ischemic hind 
limbs282. Both GCSF and GMCSF also appear to accelerate the healing process of 
damaged endothelium in animal models283;284. Studies in patients with coronary 
artery disease have shown that GMCSF improves collateral circulation285. Although 
there is no definitive evidence that GMCSF results in the mobilisation of CD34+ 
progenitor cells283;284, it does appear however to enhance the mobilisation of PCs 






Stromal derived factor 1 (SDF1) 
SDF1 also known as CXCL12 is an 8.5 kDa protein which is part of the C-X-C 
chemokine family. It is produced by multiple bone marrow stromal cell types as well 
as epithelial cells288. It has only one known receptor, CXCR4 which is expressed 
by a number of cell types including hematopoietic, immature endothelial, stromal 
and neuronal cells289. It is implicated in the migration, proliferation, differentiation of 
both murine and human hematopoietic stem cells290;291 and is involved in homing of 
putative PCs to sites of vascular and cardiac ischemia292;293. SDF1/CXCR4 murine 
knockout embryos develop multiple defects which are often fatal294. The SDF1 
gradients established between the circulation and BM compartments are thought to 
control the direction of progenitor mobilisation and migration295;296.  Platelets also 
express CXCR4 and respond to SDF-1 gradients295. The binding of platelet MPs to 
immature CD34 progenitors via P-Selectin and Mac-1 integrin receptors may be 
the mechanism by which CD34+ progenitors home to sites of thrombosis293.  
 
Vascular Endothelial Growth Factor (VEGF) 
It was initially designated Vascular Permeability Factor (VPF) by Senger et al. 297 
because of its histamine like ability to increase capillary permeability. It was 
renamed VEGF when it became evident that it also possessed some mitogenic 
activity particularly in relation to EC replication298.  It is probably the most potent 
angiogenic factor in man and other mammals, with 5 major subtypes (A-D and 
PlGF (Placental Growth Factor)) which have varying affinities for the 6 receptor 




Fig 1.4.4 VEGF subtypes and their receptor affinities  
(NRP-neuropilin receptor) 299,300.  
 
VEGF (A) is the main circulating form in mammals and plays an important role in 
regulating vascular development,  it has several distinct isoforms, with equivalent 
mouse isoforms being a single amino acid shorter (Table 1.4.5)301. It is thought 
that the VEGF121 isoform  is the most diffusible whereas VEGF165  (the main 
circulating form in man and VEGF164 in mice)  have  both matrix bound and 
diffusible components302. Mouse knockout models of VEGF164 are fatal either at 
birth or within two weeks, whereas VEGF 120
-/- results in live birth with deficient 






Table 1.4.5 VEGF, human and mouse isotypes 
Human Mouse 
VEGF 121 VEGF 120 
VEGF 145 VEGF 144 
VEGF 165 VEGF 164 
VEGF 189 VEGF 188 
VEGF 206 VEGF 205 
 
Table 1.4.6 VEGF & VEGFR knockouts 
Gene +/- -/- Phenotype 
VEGFA lethal lethal absence of 
vasculature 
VEGFB viable viable   heart size,   
recovery from MI,  
VEGFC ? lethal no lymphatic 
development 
VEGFD ? ? ? 
PLGF viable viable   angiogenesis & 
arteriogenesis 
VEGFR1 viable  viable   EC formation, 
abnormal vessels 
VEGFR2 viable  lethal    Haematopoietic 
precursors, no 
blood vessels 





Its place in prenatal vasculogenesis came to light through in utero gene targeting 
studies; VEGF is crucial during early prenatal development, important in controlling 
vascular permeability, as well as the maintenance and protection of ECs305;306. 
There is now considerable evidence that VEGF plays a vital role in 
vasculogenesis253. Firstly, over expression of VEGF in rodent muscle results in the 
formation of newly formed blood vessels and is accompanied by infiltration of the 
same area with cells which carry markers of both bone marrow lineage (Sca1) and 
endothelial lineage (CD34 and VEGFR2)307. Secondly, systemic administration of  
VEGF results in upregulation of circulating progenitor cells and enhanced blood 
flow in cardiac and hind limb ischaemia models274;308.  
 
The mechanisms controlling VEGF release are no less complex. Hypoxia appears 
to be the most potent factor in increasing both in vivo and in vitro VEGF 
expression309;310. VEGF is regulated at the transcriptional, posttranscriptional and 
translational levels311. Although there are numerous transcription factors which 
have the potential to upregulate VEGF; HIF-1α and signal transducer and activator 
factor transcription-3 (STAT3) facilitate hypoxia related VEGF expression312. A 
variety of cytokines control the expression of VEGF, including inflammatory 
cytokines such as Interleukin-1α and Interleukin-1β as well was factors which down 






Table 1.4.7 Cytokines affecting VEGF expression  
(adapted from Birk312) 
Cytokines upregulating VEGF Cytokines down regulating VEGF 
lL-1α (interleukin) IL-4 
IL-1β  IL-10 
IL-3 IFN- α (interferon) 




There are some factors which can 
cause both upregulation and down 






bFGF (basic fibroblast growth 
factor) 
EGF (endothelial growth factor) 
HGF (hepatocyte growth factor) 
KGF (keratinocyte growth factor) 
IGF-1 ((insulin like growth factor) 
Oncostatin-M 
PDGF (platelet-derived growth 
factor) 
TGF (transforming growth factor) 
TNF (tumor necrosis factor) 
MIF (migration inhibitory factor) 
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In the mouse model of venous thrombosis there is a temporal expression of VEGF 
during resolution and  increasing VEGF expression in the thrombus using plasmid 
and adenoviral upregulation enhances thrombus resolution 121;167;313.  There is also 
evidence that this is related to migration of BM cells into the thrombus, although 
the role of these cells remains unclear313. 
 
Placental growth factor (PlGF) 
PlGF is also a member of the VEGF family301. The structure of PlGF exhibits 
remarkable similarities to the structure of VEGF-A, although PlGF and VEGF-A 
have only a 42% amino acid sequence homology314. PlGF is a 46 KDa protein with 
4 isoforms. PlGF1 and PlGF3 isoforms bind to VEGFR1 only but PlGF2 also binds 
to the heparin sulphate proteoglycan (HSPG) receptor and NRP-1(neuropilin) and 











Fig 1.4.5 PlGF isoforms and their receptors  
(adapted from Ribatti315) NRP-neuropilin, HSPG-heparin sulphate proteoglycan 
PlGF-1 PlGF-2 PlGF-3 PlGF-4 
VEGFR-1 HSPG NRP-1 NRP-2 
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Complete PlGF gene knock out is not fatal as with VEGF316, but when PlGF-/- are 
exposed to ischaemic conditions i.e. myocardial infarction or following ligation of 
the hind limb artery, these mice produce a diminished angiogenic response317. In 
PlGF−/− mice, 7–14 days after ligation of the left coronary artery, there is reduced 
neovascularisation at the border of infarcted area and a reduced number of 
macrophages, suggesting that PlGF may be important in the regulation of 
angiogenesis following a pathological insult318. Administration of recombinant 
human PlGF is able to reverse the revascularisation defect and increases 
macrophage accumulation within the infarcted area. PlGF may contribute to 
angiogenesis via several mechanisms317;319;320. Studies have shown that PlGF 
enhances pathological angiogenesis by the initiation of signaling between VEGFR-
1 and VEGFR-2319. Murine PlGF amplifies VEGF signaling in endothelial cells and  
although VEGF and PlGF both bind VEGFR-1, only PlGF stimulates the 
phosphorylation of specific VEGFR-1 tyrosine residues and the expression of 
distinct downstream target genes317. This data indicates that PlGF binding to 
VEGFR-1 can somehow sensitise the VEGFR-2 receptor to VEGF321. PlGF can 
however, also directly stimulate angiogenesis via pro-angiogenic genes322. Delivery 
of recombinant PlGF stimulates angiogenesis in skin, revascularisation of 
ischaemic heart muscle and limbs, as well as the healing of diabetic wounds323.  
1.4.4 CLINICAL APPLICATION OF HAEMATOPOIETIC PROGENITOR CELLS  
Since the discovery of circulating adult progenitor cells in 1997 by Asahara252 there 
has been a rush towards developing the clinical applications of stem cell 
therapy324.   
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A large number of trials in autoimmune disease, acute and chronic myocardial 
ischaemia and stroke have shown promise although this has been hampered by 
several trials showing equivocal results324-326.  
 
Studies in myocardial ischaemia  
Early interventional studies using BMMNCs were small and non-randomised, 
studies such as the one by Strauer et al.327 showed that intracoronary BMMNC 
injection reduced infarct size at 3 months. The first randomised trial of progenitor 
cell therapy was BOOST328 (Bone Marrow Transfer to Enhance ST-elevation 
Infarct Regeneration) trial; this showed improved left ventricular function using MRI 
6 months post intervention although the 5 year results suggest that this effect is not 
longterm329. The REPAIR-AMI330 (Reinfusion of Enriched Progenitor Cells and 
Infarct Remodeling in Acute Myocardial Infarction) assessed the effect of 
intracoronary delivery of progenitor cells after angioplasty compared with placebo. 
At 4 months LV function was improved when measured by angiography, there was 
also a trend to  suggest that progenitor cell injection modified end-points such as 
repeat MI or death330. The MAGIC331 (Myocardial Regeneration and Angiogenesis 
in Myocardial Infarction with GCSF and Intracoronary Stem Cell Infusion) trial 
combined peripheral blood stem cells with GCSF infusion against GCSF infusion 
alone or no treatment as a control. Interestingly this demonstrated that although 
stem cells with GCSF improved LV function, GCSF alone produced an increased 
tendency towards coronary artery restenosis, illustrating the deficiencies in the 
understanding of basic stem cell biology331.  
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Although there is evidence from animal studies that transplantation of progenitor 
cells improves neovascularisation in ischaemic heart muscle as well as ischaemic 
hind limbs 282;332-334, clinical studies of myocardial ischaemia have been outcome 
centred and measured LV function using imaging techniques such as MRI and 
ECHO, and less focused on neovascularisation335. Using cardiac scintigraphy there 
is some evidence that cell therapy can improve tissue perfusion336 . In the 
TOPCARE-AMI study, there was improved coronary blood flow in the infarct zone 
following intracoronary injection of progenitor cells337. These studies have shown 
moderate improvement in cardiac perfusion, their biggest limitation being that the 

















Table 1.4.8 Cardiac trials based on bone marrow or mononuclear cell therapy  
using mononuclear (adapted from Jujo335).  IHF-Ischaemic heart failure, OMI-Old 
myocardial infarction, AMI-Acute myocardial infarction RMI-Recent myocardial infarction, PB-
Peripheral blood, BM-MNC-Bone marrow mononuclear cells, R-Randomised, RC- Randomised 
control, MC-Multicentre, NA-Not applicable 







OMI BM-MNCs RC 3 Effective 
ASTAMI
339
 AMI BM-MNCs R 12 Ineffective 
Beeres et al.
340
 IHF BM-MNCs NR 3-6 NA 
BOOST 
328
 AMI BMCs R 18 Ineffective 
Chen et al. 
341
  AMI BMCs R 6 Ineffective 
Fernandez-
Aviles et al. 
342
 
AMI BM-MNCs NR 6 Effective  
HEBE
343
  AMI BM-MNCs Pilot 4 NA 
Henrikx et al. 
344
(183) 





AMI BM-MNCs RC 4 Ineffective 
Kuethe
346
 AMI BM-MNCs NR 12 NA 
MAGIC
347
 AMI PB-MNCs 
(+GCSF) 
R 6 Effective 
Meluzin et al.
348
 AMI BM-MNCs R 12 Effective 
Mocini et al.
349
 RMI BM-MNCs NR 12 Effective 
Perin et al.
350
 IHF BM-MNCs NR 12 Effective 
REPAIR-AMI
351
 AMI BM-MNCs R/MC 12 Effective 
Ruan et al. 
352
 AMI BMCs R 6 Effective 
Strauer et al.
353
 AMI BM-MNCs R 4 Effective 
Strauer et al.
354





AMI PB-MNCs Cohorts 6 Effective 
TCT-STAMI
356





AMI PB/BM MNCs R 12 Effective 
Tse et al.
358
 IHF BM-MNCs NR 3 NA 
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Studies in peripheral vascular disease 
Studies in PVD have focused on using BM cells and their derivative PCs to 
improve perfusion of ischaemic lower limbs in order to alleviate pain and allow 
wound healing359-361. Animal work in rabbits, rats and mice shows that hind limb 
ischaemia results in local PC incorporation362. A limitation of these models is that 
they represent acute limb ischaemia in otherwise healthy animals as opposed to 
chronic limb ischaemia in clinical studies and as with cardiac studies BMMNCs 
have been used rather than progenitor subsets363. The Therapeutic Angiogenesis 
using Cell Transplantation (TACT)364 study was the first large clinical study using 
direct injection of BMMNCs into ischaemic limbs. Rest pain improved with BMMNC 
injection and in objective measures both ankle brachial pressure indices (ABPI) 
and transcutaneous oxygen pressure (TcP02) also improved. Several subsequent 
studies have corroborated these results (Table 1.4.9) 
 
Table 1.4.9 Mononuclear cell therapy for lower limb ischaemia 
 (adapted from Alaiti363) CLI-chronic limb ischaemia 





 PVD BMMNC RCT 6 Effective 


















CLI BMMNC CT 6 Effective 
TAM-PAD
359




The vast literature examining the impact of progenitor cell therapy in both animal 
and human models suggest that it is safe and may have a beneficial effect, the 
mixed trial results however suggest that more work needs to be done at a basic 



















1.5 HYPOTHESIS & AIMS 
1.5.1 PROJECT OVERVIEW 
The aim of this project was to examine the progenitor cell response to thrombus 
resolution using a mouse model of venous thrombosis. Flow cytometry was used to 
examine changes in circulating and bone marrow resident progenitor cell response 
to venous thrombosis.  The expression of cytokines which are known to recruit and 
mobilise progenitor cells were then measured in the thrombus, vein wall, plasma, 
and laparotomy wound tissues. The final stage of this project assessed whether 
venous recanalisation could be enhanced by upregulating circulating progenitor 
cell numbers or increasing the amount of specific progenitor cell mobilising 
cytokines within the thrombus using adenoviral technology. 
1.5.2 HYPOTHESIS 
The mobilisation and recruitment of pluripotent bone marrow derived progenitor 












The aims of this study were: 
1. to delineate the changes in the circulating and bone marrow resident progenitor 
phenotypes following thrombus formation.  
2. to determine whether there is a pattern in the local and circulating expression of 
growth factors and cytokines that are known to regulate the mobilisation and 
recruitment of bone marrow progenitor cells. 
3. to determine whether enriching the thrombus or circulation with bone marrow 
cells (with an endothelial phenotype) has a differential effect on resolution. 
4. to determine the effect of upregulating cytokines within the thrombus that are 














2.0 GENERAL METHODS 
2.1 ANIMAL MODEL 
2.1.1 OVERVIEW 
The study of venous thrombosis (VT) can be difficult in the clinical setting because 
thrombus tissue samples are not readily available from afflicted patients.  
Accurately ageing the thrombus radiologically is also not yet possible, although 
ultrasound studies examining elasticity in the thrombus have shown some initial 
promise367;368.  In addition attempting to clinically study DVT in isolation is difficult, 
as most patients have underlying health problems such as malignancy which can 
complicate any biochemical analysis369-372. A reproducible in vivo model is 
therefore advantageous in both accurately ageing the thrombus as well as 
supplying tissue samples. Several animal models have been used but rodent 
models have become popular as work in primates is now limited, both by finance 
and ethical ambiguity136;373;374. The main advantage of using mice over rats in this 
project was the availability of antibodies for progenitor antigens136. The model used 
here employs a combination of reduced blood flow and vessel wall damage to 
create thrombus in the infra-renal vena cava136.The architecture of thrombus 
formed in the mouse vena cava is similar to thrombus that is formed in humans119. 
Thrombi consist mainly of red cells and are typically laminated with platelets, fibrin, 
and leukocytes136.  The vena cava however has no valves and is therefore 
anatomically different from the human lower limb vessels where DVT commonly 
occurs140;141. The mouse model  has revealed that inducing a single component of 
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Virchow’s triad113;114 in isolation does not result in thrombosis and that it requires at 
least two components from vessel wall injury, stasis or coagulopathy136. Ligation of 
the cava alone does not produce a thrombus as consistently as when it is used in 
combination with vessel wall injury, which results in a 90% success rate136. This 
corroborates the  work of others which has shown that using either vein wall 
damage or stasis alone did not result in thrombus formation, in a rabbit model375.  
2.1.2 MOUSE MODEL 
All animal work was carried out in accordance with the Animals scientific 
procedures act 1986. Male Balb/c mice were anaesthetised using isoflurane (Abott, 
UK) anaesthetic and laparotomised. The bowel was externalised and kept moist in 
damp gauze, in order to visualise the vena cava. The renal veins were identified 
and the aorta was dissected away from the vena cava using DeBakey fine tissue 
forceps (Ethicon, UK). A 4.0 silk suture (Ethicon, UK) was placed around the infra-
renal vena cava, care was taken to avoid damaging the lumbar vessels. A silk 
suture was tied over a 5.0 prolene (Ethicon, UK) (Fig 2.1.1a) which was then 
removed to allow minimal blood flow or a ‘reduced flow’ model (Fig 2.1.1b). A 
crocodile clip (Braun Medical, UK) was then placed on the vena cava to cause 
vessel wall injury. This was repeated twice at different points on the vein, for 45 
second intervals. The animal was rehydrated with approximately 1ml of intra-
peritoneal 0.9% normal saline. Intraperitoneal Buprenorphine (Veteregesic, UK) 
was used for analgesia 50µl (0.3µg/µl). The peritoneum and skin were closed with 
4.0 PDS (Polydioxanone, Ethicon, UK) in two layers with continuous running 
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suture. The sham-control operation was identical except that a lose tie was 





















          Fig 2.1.1 Mouse model of venous thrombosis 
(a) Placement of silk suture (S) around the vena cava (VC) and the prolene 
(P), aorta (A), (b) Tied silk ligature with prolene removed 
b 
a 




2.1.3 ADMINISTRATION OF TREATMENTS 
In this model two interventional techniques were employed for delivery of 
interventions: 
 
Peripheral tail vein injection of substances into the circulation 
Peripheral tail vein injection has certain advantages over direct thrombus injection; 
it is less traumatic to the animal and allows for greater volumes of substances to be 
delivered (250µl v 10µl directly into the thrombus). At 24hrs following thrombus 
formation animals were re-anesthetised for tail vein injection (Sec 2.1.2).  The tail 
was cleaned using alcohol and a 1ml, 25G insulin syringe (BD, UK) used to inject a 
volume of up to 250µl of solution into either the dorsal or lateral tail vein (Fig 2.1.2). 
After removing the needle, direct pressure was used to prevent further bleeding 


















Direct thrombus injection  
Direct thrombus injection was chosen for adenoviral upregulation to concentrate 
chemokine upregulation and prevent hepatic sequestration of the virus376. Under 
isoflurane anaesthetic, the primary laparotomy incision was re-opened and the 
small bowel placed in moist gauze as described above. The thrombus was injected 
using 33G needle (Hamilton, Switzerland) and 50µl syringe (Hamilton, 
Switzerland), where it appeared most solid to reduce the risk of post injection 
haemorrhage.  Once the injection was complete any haemorrhage was controlled 
with direct pressure using a cotton bud (Johnson & Johnson™). Analgesia, 
hydration and wound closure were as previously described (Sec 2.1.2).   
2.1.4 TISSUE PROCESSING FOR FLOW CYTOMETRY AND ELISA 
Animals were anaesthetised using isoflurane anaesthetic, the primary laparotomy 
wound was reopened and the heart punctured with a 25G needle (BD, UK).  Blood 
was collected in a 2.5ml syringe (BD, UK) and placed immediately in an EDTA tube 
(BD, UK). After exsanguination, thrombus, vein wall and wound tissues were 
harvested, snap frozen and stored at -80°C. Femur bones were also harvested 
with sharp dissection and stored at 4°C in sterile saline until BM extraction was 
carried out for flow cytometry (Sec 3.2.5). 
 
Frozen tissues were homogenized for 2-3mins on ice using mortar and pestle 
(Eppendorf, UK), wound, vein wall and thrombus samples were all homogenised in 
PBS with a cocktail protease inhibitor III (0.5ml/mg) (Calbiochem, UK) added to 
prevent protein degradation.  
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Samples were placed in Eppendorf vials and centrifuged at 20,000 X g for 10mins 
at -4°C and the supernatants were collected for both ELISA and protein analysis. 
The protein content of aliquoted samples was calculated using a Bradford Assay 
(Appendix1A).  
 
2.2 CHEMOKINE ANALYSIS 
2.2.1 INTRODUCTION 
A large number of chemokines have been implicated in the mobilisation of bone 
marrow progenitor cells. VEGF, PLGF and SDF-1, GCSF and GMCSF discussed 
in the introductory chapter to this thesis all appear to play a role377;378. The aim of 
this section of work was to examine the temporal expression pattern of these 
chemokinetic proteins during thrombus resolution. Thrombus, vein wall, plasma 
and laparotomy wound (control) protein extracts were all analysed using ELISA 
(enzyme linked Immunosorbent assay).  
 
Several techniques can be used for protein analysis; immunohistochemistry for 
protein localisation, Western blotting and ELISA for protein quantification. ELISA 
has however, proven to be an efficient and accurate method for protein 
quantification when suitable antibodies are available. 
2.2.2 ELISA  
ELISA is a technique used to detect a specific protein in a given solution. The 
limited amount of mouse tissues available makes it difficult to perform multiple 
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standard sandwich ELISAs. The amount of plasma extracted from mouse blood is 
limited to a total volume of roughly 300l which if undiluted is only sufficient for a 
single ELISA. Combining both multiplex and standard ELISA systems allowed 
analysis of a larger number of chemokines and limited animal usage. Although the 
Sandwich ELISA technique has become one of the most popular methods of 










ELISA techniques are all based on the interaction of an antigen with an antibody. 
In a single antibody system the primary antibody is linked to an enzymatic reaction 
which results in a colour change in a specific substrate. This colour change is then 
quantified using an absorbance plate reader. The greater the colour change the 


















Fig 2.2.1 Direct ELISA 
 
 
The direct ELISA (Fig 2.2.1) method uses a single primary labelled antibody to 
detect the antigen. It has the advantage of being a single step process, conjugation 
of the primary antibody to the chromogenic enzyme however, may affect its antigen 
binding ability. Signal amplification is also limited with a single antibody system 
making it less efficient in detecting small protein concentrations. 
 
Indirect ELISA 
In this system there is a secondary antibody which is conjugated to the 
chromogenic enzyme. Its advantages are:  a single conjugated secondary antibody 
can be used in multiple ELISAs; if the secondary antibody binds to multiple 











Its drawback is that it is a two stage process with the potential risk of cross 
reactivity between the secondary antibody and the antigen resulting in a non-
specific signal (Fig 2.2.2). 
 
 











Fig 2.2.2 Indirect ELISA 
 
Sandwich ELISA 
The Sandwich ELISA system is a type of indirect ELISA also using a secondary 
enzyme linked antibody. It differs from the indirect system in that there is also 
capture antibody which holds the antigen on the ELISA plate thereby reducing the 
interaction from non-specific proteins. Adding in a third antibody however raises 















Multiplex ELISA  
Multi-Plex technology enables the quantification of multiple proteins from a single 
sample. It is essentially a sandwich ELISA, but rather than only one capture 
antibody and one detection antibody it uses multiple antibodies. The luminescent 
reaction created is measured at different spots within the same well for different 
analytes. Below is a photograph of the luminescence created by reactions 
occurring within the same well (Fig 2.2.3); the luminescence for each spot within 
the well is photographed using a charged coupling device (CCD) camera. In the 
Perbio© system luminescence is created using the SuperSignal ELISA Femto 
Maximum Sensitivity Substrate, and the plate is placed under the CCD camera in a 
light-tight environment.  
 
The CCD chip is exposed to the image over a specific exposure time and a 
digitised image is acquired and displayed on a monitor. The Perbio© CCD image 
analysis system calculates exact values (pg/ml) for unknowns from standard 























   Fig 2.2.3 Mulitplex ELISA 
 
2.2.3 STANDARD SANDWICH ELISA PROTOCOL 
The protocol for the PlGF ELISA is given below, it is derived from the R&D Duo kit 
manual and follows the same set of steps as the SDF1, GMCSF, GCSF and VEGF 
ELISA, individual ELISA kit components and working dilutions are described in 
Table 2.2.1.  
 
PlGF Protocol 
A 96 well plate (NUNC, UK) was coated with 100l of the appropriate dilution 




The plate was washed using a plate washer with 400l of wash buffer (0.05% 
Tween© 20 in PBS, pH 7.2-7.4 (R&D, UK)) per well X 3. Then 400l of reagent 
diluent (1% BSA in PBS, pH 7.2-7.4, 0.2µm filtered) was added to each well and 
incubated for 1hr. The wash step was repeated and100l of PlGF protein sample 
standard was added in triplicate to the left hand wells (serially diluted from a top 
standard of 100pg/ml down to15pg/ml). 100l protein samples were then added in 
duplicate and incubated for 2hrs. The wash step was repeated and 100l 
(200ng/ml) of detection antibody (goat anti-mouse PlGF) was added to each well 
and incubated for 2hrs. The wash step was repeated and 100l of streptavidin 
HRP (1/200, from kit) working dilution was added and incubated for 20mins. The 
wash step was repeated and 100µl of TMB substrate solution (Thermoscientific, 
UK) (1:1 mixture of colour reagent A (H202) and colour reagent B 
(Tetramethylbenzidine)) was then added to each well and incubated for 20mins. 
Finally 50µl of 1M H2SO4   was added to each well to stop any further reaction. The 
plate was analysed using a spectrophotometer at 450nm. Below is an example of 
the standard curve generated from the PlGF standards (Fig 2.2.4).  




Table 2.2.1 ELISA kit solutions and working concentrations 
ELISA GCSF VEGF SDF1 GMCSF 





































































Fig 2.2.4 PlGF standard curve 
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2.3 HISTOLOGY  
2.3.1 FROZEN SECTION  
IVC and thrombus were excised together just below the left renal vein to the 
bifurcation of the common iliac veins.  Vein wall and thrombus en mass and 
spleens were mounted using O.C.T. (optimal cutting temperature) compound 
(Tissue-Tek, UK) and frozen in liquid nitrogen. A microtome was used to cut 10μm 
tissue sections at 300μm intervals throughout the length of the vein or spleen and 
placed on slides coated with Vectabond (Vector Labs, UK) which were air dried for 
1hr (18-20°C). Coverslips were mounted using 1-2 drops of Vectashield mounting 
medium with DAPI (Vector Labs, UK) and images were captured using a 
microscope-mounted colour digital camera (CoolSnap Pro CF) and motorised 
stage (ProScan, Datacell, UK). 
2.3.2 PARAFFIN SECTION 
IVC and thrombus were excised together as above (Sec 2.3.1). Tissue was fixed in 
10% formalin, dehydrated through graded alcohols and processed automatically for 
paraffin embedding (Tissue-Tek, UK). Using a microtome 5μm sections were cut at 
300μm intervals along the entire length of the vein. Images were captured using a 
microscope-mounted colour digital camera (CoolSnap Pro CF) and motorised 




2.3.3 HAEMATOXYLIN & EOSIN STAINING  
Tissue sections were warmed for 20mins at 40°C and deparaffinised in xylene for 
2mins after which they were rehydrated by processing through graded alcohols to 
water. They were stained with Mayer’s haematoxylin dye (Sigma, UK, which stains 
nuclei blue) for 5mins (18-20°C) and washed in distilled water for 5mins. 
Differentiation was carried out by immersion in acid alcohol (1% HCl in 70% 
ethanol, BDH) for 3-5 seconds. The sections were washed again as above and 
stained with eosin dye which stains cytoplasm red (Sigma, UK) for 2mins (18-
20°C). Sections were dehydrated through graded alcohols to xylene and mounted 
on glass slides (BDH, UK) using DPX resin. Sections were visualised using a light 
microscope (Leitz LaborLux S, Leica, UK) and images were captured using a 
microscope mounted camera (Coolpix 990, Nikon).  
2.3.4 IMAGE ANALYSIS 
All sections were analysed using a Leica (Leitz DMRB) microscope at X5 
magnification. Images were then captured using CoolSnap Pro CF colour digital 
camera. Images were typically captured whole or tiled to create a single composite. 
Image analysis was then carried out using the Image Pro Plus package™ (Media 
Cybernetics, USA) with specific macros to allow efficient analysis of up to ten 
images per thrombus (Sec 2.3.5).  
2.3.5 ANALYSIS OF THROMBUS SIZE AND RECANALISATION 
The Image Pro Plus package was calibrated using a 1mm graticule. Recanalisation 




vein wall. Using a highlighting tool these areas were drawn around and identified 
as areas of interest (AOI). After this the vein wall itself was traced around and the 
AOIs were subtracted from it as a function of the macro (Fig 2.3.1). This would 
generate two numbers; the area of thrombus recanalisation per section and also 
the area occupied by the thrombus. This calculation was performed for 
approximately 10 sections per thrombus from which the mean percentage 


























      Fig 2.3.1 Cross section of vena caval wall with thrombus  
(A) schematic of a thrombus in its long axis, cross-sectioned (B) sample cross 
section: dashed line represents areas of interest (AOI) which can be calculated 
as a percentage of the total vein circumference. T (thrombus), VC (vena cava)  
AOI represented 
by dashed line 













2.4. PROGENITOR CELL TRACKING  
The ability to track the distribution and migration of biologically active cells in vivo 
can be invaluable in determining the mechanisms underlying cell based therapies. 
Although monocyte migration into the resolving mouse thrombus has been 
previously demonstrated, it is unknown if progenitor cells follow a similar course119. 
Cell tracking can be performed through both direct and indirect labelling 
techniques. Direct labelling, as used here has the advantage of being a relatively 
straightforward process that is not limited by cell modification. Its major 
disadvantage is that the label can be lost or diluted during subsequent cell division. 
Indirect labelling is a more complex process that requires a reporter gene, which if 
it remains stable can be indefinitely measured in the labelled cells progeny. The 
PKH26 system used here allows the labelling of the lipid membrane of the cell with 
a fluorescent dye which was used here to distinguish the native progenitors from 
the transplanted bone marrow mononuclear cells. 
2.4.1 PKH26 CELL LINKER KIT METHOD 
(The following is adapted from the PKH 26 red fluorescent linker kit (Sigma, UK) 
instruction manual, all steps were performed at 18-20°C) 
 
Approximately 2 X 107 BMMNCs were placed in a 15ml conical tube (Falcon BD, 
UK) and washed once in Dulbecco’s modified eagles medium (DMEM). Cells were 
centrifuged at (400 X g) for 5mins into a loose pellet (18-20°C).The supernatant 




1ml of diluent C (from kit) was added and the cells were resuspended, pipetting to 
insure complete dispersion (do not vortex). Immediately prior to staining, 4 X 10-6 
molar PKH26 dye was prepared in a 15ml falcon conical tube using diluent C. 1ml 
of 2X cells was then added to 1ml of 2X dye, pipetting to mix. Cells were incubated 
at 25°C in a water bath for 2-5mins. Periodically, the tube was inverted gently to 
assure mixing during the staining period. The staining reaction was stopped by 
adding an equal volume of DMEM with 1% bovine serum albumin (BSA, R&D 
UK).The cells were then centrifuged (400 X g, 10mins at 25 °C) to remove them 
from the staining solution. The supernatant was aspirated and the cells washed as 
above a further 3 times with DMEM. Cells were then suspended in DMEM at a 
concentration of approximately 4 million cells/ ml (1million cells/ 250µl). 
2.5 CELL CULTURE  
Cell culture was used to grow and characterise the adenoviruses used for the 
interventional studies. Human Embryonic Kidney (HEK) 293 cells have been 
transformed by the introduction of approximately 4.5 kb of viral genome into the 
human chromosome 19 of the HEK cell line. It is a stable cell line which produces 
the adenovirus E1 gene in trans allowing the replication of E1-deleted 
adenoviruses such AdPlGF and AdSDF1.  
2.5.1 HEK293 CELL CULTURE 
Frozen HEK 293 cells (Stratagene, UK) were thawed by brief immersion in a 37°C 




The contents of the vial were diluted in supplemented growth media (DMEM 
(Lonza, UK) +10% FBS (Gibco, UK) and transferred into a T25 flask (Falcon BD, 
UK). Cells were placed in a 37°C, 5% CO2, humidified incubator. Cell morphology 
and viability were verified under a microscope after 24hrs (healthy cells display a 
flat morphology and adhered well to the plate, Fig 6.2.1A).  Old growth medium 
was aspirated and replaced with fresh, pre-warmed (37°) growth medium at 24-
48hr intervals. Cell cultures were then expanded as required. Cells in culture were 
passaged (Sec 2.5.2) every 2–4 days, when they reached 70–80% confluency.  
2.5.2 HEK 293 CELL PASSAGE 
Old growth medium was aspirated and the cells were washed once with pre-
warmed sterile PBS (containing no Ca2+ or Mg2+). 1–2mls of trypsin-EDTA 
solution (Sigma, UK) was added for 1–2mins, until cells detached. Trypsinisation 
was terminated by the addition 5–10mls of growth medium. Cells were then 
transferred to the desired number of culture flasks containing medium and the 






3.0 OPTIMISATION OF FLOW CYTOMETRY FOR 
HAEMATOPOIETIC PROGENITOR CELLS 
3.1 FLOW CYTOMETERY 
3.1.1OVERVIEW 
The aim of this section of work was to determine whether venous thrombosis has 
an effect on the number and phenotype of circulating and bone marrow resident 
progenitor cells. Flow cytometry was used to enumerate HPCs in the blood and BM 
by using antibodies against cell surface markers to Sca-1, CD34 and VEGFR2 
(DC101).  
3.1.2 THE FLOW CYTOMETER 
Flow cytometry is a technique that is ideally suited to identifying and counting 
populations of cells in solution. Single cells in a continuous fluid stream are passed 
through one or more laser beams which cause light to scatter and fluorescent dyes 
to emit light at various frequencies. Photomultiplier tubes (PMT) convert light into 
electrical signals and the data is collected on a computer. Three types of data can 
be derived from the analysis: cell size, cell complexity (i.e. granularity) and lastly 
cell populations can be quantified by tagging them with a variety of fluorescently 
labelled antibodies208. Cytometers have gone through some major advances over 




For this project we used a FACSCalibur®, single laser cytometer (BD, UK, Fig 
3.1.1). The flow cytometer consists of three main components: 
 
(1) Flow Cell: This is a fluidic system by which cells are drawn up into the 
machine through an external port. The purpose of this is to keep the cells at 
the centre of a fluid stream, in single file; so that only one cell at a time is 
targeted by the laser.  This process is known as “Hydrodynamic Focusing” 
(Fig 3.1.2)380.  
 
(2) Optical System:  Basic machines are fitted with a single laser e.g. argon, 
which delivers approximately 15mW at 488nm as a light source. As the 
single cells filter into the cuvet they are hit by the laser. Light is then 
refracted off the cells and the degree of refraction, which is dependent on 
the size and granularity of the cells, is detected by silicon photodiodes or 
photomultiplier tubes that convert light into electrical impulses. The refracted 
light from the cells is interpreted as forward scatter (Fsc: cell size) and side 
scatter (Scc: cell granularity). An example of a peripheral blood forward and 
side scatter dot-plot is shown below (Fig 3.1.3).  
 
(3) Analogue-Digital Convertor: Converts the light signals as detected by the 
















   Fig 3.1.1 Flow Cytometer 
 
 
 Fig 3.1.2 Flow cytometer tip 
 The sheath fluid (Phosphate buffer) draws the cells into a central chamber 
 by creating a single cell stream, ‘hydrodynamic focusing’. 
Sheath fluid 
Injector  





Fig 3.1.3 Scatter plot of mouse whole blood after red cell lysis (white cells are 
displayed in three distinct groups)  
 
3.1.3 MEASUREMENT OF CELL POPULATIONS 
Measurement of specific cell populations within the scatter plots is performed using 
fluorophore tagged antibodies. A fluorophore is a molecule that when excited by a 
laser, emits fluorescence. Fluorescence detectors within the cytometer are fitted 
with filters that only percieve light, different in colour to that of the laser. Argon 
produces a blue laser so typical filters are red, orange and green, this means that 
any light detected by these receptors is only generated by antibody labelled cells 
which have crossed the path of the lasers. Some commonly used fluorophores are 









consists of red 















FITC 488 525 Green 
PerCP 488 675 Red 
Pe 488 578 Yellow 
Alexa Fluor 405 421 Turquoise 
 
FITC  Fluorescein isothiocyanate  
PE  Phycoerythrin 
PerCP  Peridinin-chlorophyll-protein complex 
 
An antibody bound to a cell will emit the typical fluorescence for that fluorophore 
e.g. FITC will produce a green emission. To adjust for non-specific antibody 
signalling, a non-specific IgG antibody conjugated to the same fluorophore should 
be used as a control. A single laser machine can detect up to three fluorescently 
labelled antibodies per sample. 
3.1.4 FLOW CYTOMETRIC DATA ANALYSIS 
Data was analysed using the flow cytometry-specific software package, Win MDI, 
which is a freely downloadable software package available from the internet 
(http://flowcyt.salk.edu/software.html).  The software can be used to produce two 
dimensional histograms known as dot plots for data analysis. This allows cell 
populations to be selected and quantified for the presence or absence of specific 




system is to plot Fsc versus (v) Scc (see Fig 3.1.4 (i)), fluorophore, channel 1 
(FL1) against fluorophore channel 2 (FL2), and FL1 against channel 3 (FL3) (Fig 
3.1.4 (iv) & (v)).  Each fluorophore should produce a signal in its respective 
channel (Table 3.1.2).  
 
               Table 3.1.2 Channel, antibody and fluorophore optimised  
CHANNEL ANTIBODY FLUROPHORE 
FL1 VEGFR2 (DC101) FITC 
FL2 CD34 Pe 
FL3 Sca1 PerCP 
 
Using the Fsc v Scc plot, populations of interest can be selected and analysed for 
the presence or absence of fluorescently labelled antibodies bound to the antigens 
of interest. The selected area of interest is known as a ‘region’, a region can then 
be used to either exclude or include data from any further analysis. This allows 
analysis of specific cell phenotypes and reduces the impact of non-specific 
signalling on data interpretation. Fig 3.1.4 (a) is a typical Fsc v Scc plot, the 
mononuclear region has been selected from this plot. Fig 3.1.4 (b) is a dot plot of a 
VEGFR2 versus CD34 for the same data without the application of gating (region 
selection or exclusion). This results in a large amount of non-specific labelling, 
making data interpretation difficult. Fig 3.1.4 (d) has been ‘gated’, which means the 




To account for auto-fluorescence and non-specific binding, a control sample 
containing fluorescently labelled non-specific IgG of the same subgroup is used to 
set the quadrants to confine background staining to the bottom left quadrant (Fig 
3.1.4 (c)). Fig. 3.1.4 (d) shows positive cells in both the VEGFR2 channel and the 
CD34 channel, cells in the larger upper right quadrant are positive for both 
VEGFR2 and CD34 and are known as double positive. Gating also enables 
elucidation of triple positive cells. Fig 3.1.4 (e) is a dot plot which has been gated 
for region 1 and region 2, this data has then been plotted in the VEGFR2 v Sca1 
dot plot. Region 1 is selected for mononuclear cells and region 2 has been 
selected for the population of mononuclear cells positive for both VEGFR2 and 
CD34. Plotting the same data in the VEGFR2 v Sca1 plot selects for triple positive 





























     
 
    
  
 
   
 

















Fig 3.1.4 Dot plots using regions 
and gates 
VEGFR2 








Ungated dot plot 
IgG control VEGFR2 
 




































3.1.5 VOLTAGE SETTING 
Optimising the voltage settings on the flow cytometer is performed during the set-
up stage, before data collection can begin. The voltage is set according to the size 
and the complexity of the cells being analysed. This reduces the impact of non-
specific staining on data collection. Using a sample containing only control 
antibodies the voltage is either increased or reduced to place all non-specific 
staining into the bottom left quadrant or the first decade of the log plot (Fig 3.1.4 
(c)).  
 
Secondly, fluorescence emitted from one fluorophore can overlap with the 
emission from that of another fluorophore being used in the analysis of the same 
blood or tissue sample i.e. the fluorescent signal form FITC overlaps with signal 
from PE (Fig 3.1.5). This is a potential problem when using more than one 
antibody and can be overcome in two ways: (1) is to use antibodies which have 
markedly different emission spectra (2) to perform a compensation experiment in 
which spectral overlap is compensated for by manipulating the voltage settings. 
For cells present in only small quantities the use of compensation beads 












    
            
Fig 3.1.5 Overlapping emission spectra of commonly used fluorophores 
FITC-Fluorescein isothiocyanate, ECD-Energy Coupled Dye, PE-Phycoerythrin, 
PC5- CyChrome Tricolor, PerCP- Peridinin chlorophyll protein 
 
3.1.6 THRESHOLD  
Setting threshold allows exclusion of cells or cellular debris of a certain size and 
granularity from the analysis. This reduces the signal to noise ratio, any cells 
excluded from analysis using the threshold function are not recorded as data 
points.  
500 600 700 
 Laser 
488nm FITC PE PC5 ECD PerCP 




3.2 OPTIMISATION OF COMPENSATION SETTINGS 
3.2.1 INTRODUCTION 
In order to run experiments with multiple fluorescently labelled antibodies, the 
voltage settings are manipulated to reduce the impact of spectral overlap from the 
any fluorophore labelled antibodies used (Fig 3.1.5).  
 
3.2.2 BASIC SETUP AND COMPENSATION USING LYSED WHOLE BLOOD 
Method 
Five samples of mouse blood were required to set up a compensation experiment 
for three antibodies; one containing all three non-specific IgG isotype control 
antibodies, one containing the three antibodies of interest and three further 
samples each containing one antibody of interest only.  
 
First blood containing all three IgG isotypes was analysed, the voltage settings 
were adjusted to place all non-specific signal generated in the bottom left quadrant 
(Fig 3.2.1(a)). Antibodies of interest were then tested individually to look for 
spectral overlap in their fluorescence, i.e. individual antibodies should only produce 
positive signals in one channel. The voltage settings were then altered and fixed to 
compensate for all overlapping spectral signals. 
 


















(a) Isotype control dot plot (b) Sca1 PeCy7 fluorochrome 
prior to compensation 
(d) Strong Sca1 PeCy7 signal 
using compensation beads  
(c) Sca1 PeCy7 fluorochrome 



























3.2.3 SETTING COMPENSATION SETTING USING BEADS 
 
Methods 
The described method is based on the manufacturer’s instructions, all steps were 
carried out at 18-20◦C unless otherwise stated: 
 
Adjustment of the voltage settings was performed as above to exclude non-specific 
IgG signalling. The beads were then used only to compensate for spectral overlap. 
200μl of stain buffer was added to three 15ml conical tubes (Falcon BD, UK) and 
approx. 120μl (2 drops) of antibody positive and 120μl of antibody negative beads 
were added to each tube (CompBeads, Invitrogen, UK). The antibody requiring 
compensation e.g. Sca1 was then added to each tube, the concentration of 
antibody used was according to manufacturer’s instruction. 2mls of stain buffer was 
added to each sample of beads and centrifuged (600 X g for 5mins).The 
supernatant was discarded and samples resuspended in 1.5mls of stain buffer. 
The voltage settings were then adjusted to compensate for spectral overlap.   
 
Results 
Illustrated in Fig 3.2.1 are the dot plots generated during the Sca-1 compensation 
study. Fig 3.2.1 (a) accounts for fluoresence generated from the non-specific 
binding of the isotype control antibodies. It is filtered into the lower left quadrant by 
adjusting the voltage settings. The fluoresence generated by the Sca-1 antibody 
produced some spectral overlap into FL2 ((Fig 3.2.1 (b)). Adequate compensation 




CD34 and VEGFR2 antibodies were similarly compensated for background 
fluoresence and spectral over lap. In (Fig. 3.2.1 (d)) the Sca-1 antibody 
compensation using beads produces a distinct dot plot.  
 
Conclusion  
After testing both methods, compensation beads were used as the signal from 
VEGFR2 /DC101 was insufficient to adequately compensate for its spectral 
overlap. 
3.2.4 WHOLE BLOOD PREPARATION FOR FLOW CYTOMETRY 
Approximately 800μl -1000μl of blood was harvested per animal and split into two 
replicates of 400μl. One replicate was used for the antibodies of interest and one 
for IgG isotype controls.  
 
FACS protocol for mouse blood 
All steps were carried out at room temperature (18°-20°), centrifugation was always 
400 X g and incubations were performed out of direct light 
 
 400μl of whole blood was aliquoted into 15ml conical tubes (Falcon BD, UK) 4μl 
(1μg/ul) Fc receptor block (BD, UK) was added to each replicate and incubated for 
15mins. Titrated concentrations of the antibodies were then added and incubated 
for 30mins (Sec 3.3.1). Equivalent concentrations of IgG isotypes were added to 
the second replicate, to serve as a control. 2mls of stain buffer* (PBS (Phosphate 




(w/v)) was added to each sample and centrifuged for 5mins, the wash step was 
repeated. After centrifugation the supernatant was removed and 8mls of lysis 
buffer (Pharmolyse®, BD Biosciences, UK) was added. This was incubated for 
10mins (added at a ratio of 2mls per 100μl of blood volume). The sample was 
centrifuged for 5mins and the supernatant removed. Samples were resuspended in 
1-2mls of stain buffer for FACS analysis. 
 
3.2.5 BONE MARROW PREPARATION FOR FLOW CYTOMETRY 
 
All the following steps were carried out at room temperature (18°-20°) and 
centrifugation was always 400 X g. 
 
The ends of a mouse femur were excised using a scalpel blade, this allowed 
access to the femur lumen containing BM. BM was flushed out using a 30G (BD, 
UK) needle into a sterile petri dish with 10% stain buffer (phosphate buffer with 
10% (v/v) heat inactivated foetal calf serum and 0.09% sodium azide); a 1-2mls 
suspension was centrifuged for 5mins. The supernatant was discarded and the red 
cells in the pellet were lysed for 30secs Pharmolyse®. A further 2mls of modified 
stain buffer was added to the sample and it was centrifuged for 5mins, the 
supernatant was again discarded. Cells were resuspended in 2mls of modified 
stain buffer and filtered through a 70μm filter (BD). A haemocytometer was used to 
count the cells, and each sample was diluted to contain approximately 1-2million 




incubated for 30mins. Titrated antibody concentrations (Sec 3.3.1) were added to 
the bone marrow cells and a 30mins incubation performed. Samples were washed 
with 2mls of modified stain buffer and centrifuged for 5mins; the supernatant was 
discarded and cells were resuspended in 1-2mls of modified stain buffer for FACS 
analysis.  
3.3 OPTIMISATION OF FLOW CYTOMETRY FOR MOUSE HPCS 
3.3.1 INTRODUCTION 
The definition of progenitor cells has continued to develop over the last decade221 
but in this project the HPC population was defined as Sca-1+CD34+VEGFR2+ 
HPCs194;208;221;225. In order to examine the circulatory and BM resident HPC 
response to venous thrombosis, the cytometer settings were first optimised for the 
antibodies of interest. This was initially attempted using only the commercially 
available mouse antibodies. 
3.3.2 DETECTION OF SCA-1+CD34+VEGFR2+CELLS 
Methods 
Mouse blood was collected (Sec 2.1.4) and stained as described with general 
FACS protocol (Sec 3.2.4). Sca1 (BD, UK) CD34 (Serotec, UK) and VEGFR2 (BD, 
UK) were used at the optimal titrated dilutions (Table 3.3.1). Duplicate samples 
were run using the (BD) FACSCalibur®, approximately 5 X105 cells were counted 




The specificity of the antibody was calculated by excluding the number cells 
labelled with non-specific IgG as a percentage of the number of cells labelled with 
the antibody of interest. 
 







Sca1 0.2 0.04 Pe-Cy7 
CD34 0.5 0.05 PE 




Table 3.3.2 shows the numerical signal generated from antibodies and IgG 
controls on the same blood sample. The Sca1 antibody had a greater than 99% 
specificity and the CD34 antibody a greater 90% specificity, VEGFR2 was however 
less than 40% specific. Fig 3.3.1 compares the fluorescent signal generated from 
the Sca1, CD34 and VEGFR2 antibodies with their IgG isotypes. Clear differences 
were seen between the isotypes and the antibody samples for Sca1 and CD34, but 
for the VEGFR2 antibody and its respective IgG control, the fluorescence 









             Table 3.3.2 Sca-1, CD34, VEGFR2 positive cell populations 
Sample % of positively labelled 
mononuclear cells 
Sca-1 CD34 VEGFR2 
1 Isotype 0.0034 0.06 0.0021 
 Antibody 8.01 0.73 0.003 
2 Isotype 0.0013 .049 0.001 
 Antibody 7.34 0.68 0.002 

















      Fig 3.3.1 Dot plots of mouse blood using fluorescent antibodies 
(A) and (B) compare both CD34 and VEGFR2 antibodies against their IgG 
controls, (C) and (D) compares Sca1 and CD34 against their isotypes. Double 












































3.3.3 FURTHER ASSESSMENT OF ANTI-VEGFR2 FOR FLOW CYTOMETRY 
Method 
VEGFR2 was assessed in isolation using a new antibody and isotype control 
purchased to exclude contamination. The FACS protocol (Sec 3.2.4) was used 
with two different concentrations of VEGFR2: 0.025mg/ml and 0.1mg/ml. 
Specificity was calculated as described in section 3.3.2.  
 
Results 
Reducing the antibody concentration did not reduce the level of non-specific 
binding and it remained greater than 60% (Table 3.3.3). 
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The commercially available VEGFR2 antibody was found to be unsuitable for flow 
cytometry and the alternative antibody DC101 clone acquired from Imclone™ 
systems was conjugated and tested. 
 
3.3.4 CONJUGATION OF DC101 (VEGFR2) FOR FLOW CYTOMETRY   
Method 
The DC101 antibody clone was conjugated to fluorescein isothiocyanate (FITC) 
using a commercially available conjugation kit (Invitrogen, UK).  Conjugation was 
performed as per the data sheet, the main steps of the procedure are listed below: 
 
200µl of DC101 was added to the vial (A, kit component) which contained the stir 
bar (small metal bar already in place for stirring). 20µl of 1M Bicarbonate pH~8.4 
was then added to vial (A). 50µl of Dimethylsufoxide (DMSO) was added to a vial 
of fluorescein (B, kit component), the amount of dye required for conjugation was 











   mg/ml protein     =        X 0.2 ml   X 590 X 100 X MR 
                                              MW of protein 
 
0.2 ml - volume of protein (antibody solution) 
590 – MW (molecular weight) of the reactive dye 
100 -unit conversion factor 
The MW weight of most IgG is 145,000 
MR (molar ratio) of dye to protein in the reaction mixture, which is related to the 
concentration of the antibody; for an antibody concentration of 3mg/ml it should be 
20-25.  
 
                2 X 0.2   X 590 X 100 X 22  = 3.6 µl 
                                                  145,000 
 
       3.6µl of reactive dye solution was then added to vial (A) and it was stirred for 1 
hour at (18-20°) out of direct light. The contents of vial (A) was placed drop wise 
into the filtration column (kit component, separating bound and unbound 
fluorescein). The filtration column and attached collection tube (kit component) 
were then centrifuged (1100 X g for 5mins, 18-20°). The collection tube ultimately 




VEGFR2 (DC101) was then assessed using an appropriate isotype control at three 
different concentrations: 5µg/ml, 10µg/ml and 20µg/ml (Sec 3.2.4) 
 
Results  
10µg/ml of VEGFR2 (DC101) demonstrated only 6% of false positive staining 
(Table 3.3.4), lowering the concentration of DC101 further resulted in significant 
loss of signal. The signal strength at 10µg/ml of DC101 is also shown in dot plot 
form (Fig 3.3.2). 
 
Table 3.3.4 Evaluation of VEGFR2 (DC101) antibody 
                                                                 
Amount of isotype or antibody (µg/ml) 
5 10 20 
% binding  IgG Isotype  
 
0.04 0.06 0.56 
 VEGFR2 
(DC101)   
0.062 0.87 1.8 
 















Fig 3.3.2 Dot plots for (a) IgG isotype signal, (b) DC101 signal 10µg/ml 
 
3.3.5 OPTIMISATION FOR SCA-1+CD34+DC101+ CELLS 
Sca1 (BD, UK) CD34 (Serotec, UK) and DC101 (Imclone™, USA) were used at the 
titrated dilutions (Table 3.3.1, Sec 3.3.4). Two sets of samples were run with all 
three antibodies and two samples were run with all three isotypes. Triple positive 
cells were calculated using the WinMDI 2.9 region and gating function (Sec 3.1.4). 
Approximately 500,000 cells were counted per sample and the specificity of the 
antibodies was calculated as described above. 
 
Results 
Using all three antibodies the specificity of the antibodies was increased with only 
approx 5% false positive staining (Table 3.3.5). Both Fig 3.3.3 (A) and (B) show 
double positive CD34+VEGFR2+ cells in region 1 and Sca1+ VEGFR2+ cells in 







reanalysed for cells positive for all three antibodies shown in Fig 3.4.3 (D), for 
comparison triple isotype positive cells are also shown in Fig 3.4.3 (C). Comparing 
(C) and (D) it can be seen that the triple positive antibodies are highly specific and 
there is minimal background fluorescence from the isotype antibodies.  
 
          Table 3.3.5 Specificity of Sca1+CD34+VEGFR2+ antibodies 
                                                                 
Sample 
 1 2 




Sca1+CD34+DC101+   
0.021 0.034 
 























Fig 3.3.3 Dot plots using regions and gates to show triple positive cells  
(A)&(B) show double positive cells in regions 1 + 2,(C) is an example of the 
number of triple positive isotype control cells, with (D) showing the actual 
triple positive Sca1+CD34+DC101+ cells. 
Sca1,CD34, 
































The above studies demonstrated that Sca-1 and CD34 binding was specific but 
that the commercially available mouse VEGFR2 demonstrated a high level of non-
specific binding. Antibody contamination and dilution were considered as possible 
reasons for this non-specificity but excluded through further assessment; because 
of this the VEGFR2 antibody (BD-555308) from BD Biosciences was concluded to 
be unsuitable for use in flow cytometry. A novel form of the VEGFR2 named 
DC101from Imclone™ Systems was used as an alternative to the commercially 
available VEGFR2 (BD, UK)381. A small quantity of this antibody was donated to 
this project by the manufacturers. DC101 (VEGFR2) was conjugated with FITC 
and then optimised for use with Sca1 and CD34 antibodies. In combination these 














4.0 THE PROGENITOR RESPONSE TO VENOUS 
THROMBOSIS 
4.1.1 INTRODUCTION 
Progenitor cells have for over a decade been implicated in post-natal 
vascularisation194;366;382. In venous thrombosis, bone marrow Tie-2 positive cells 
are recruited into the resolving thrombus in a temporal pattern. These cells were 
once thought to be EPCs but are now believed to be a  subset of pro-angiogenic 
monocytes209.  Furthermore the direct upregulation of VEGF in the murine 
thrombus results in greater numbers of circulating Sca1+ (BM marker) cells and 
enhanced thrombus resolution313.  In an effort to further classify the progenitor 
response to venous thrombosis, this study examined the temporal changes in 
circulating and BM resident Sca1+CD34+VEGFR2+ HPCs following induction of 
thrombus, using flow cytometry. The growth factor or cytokine VEGF has 
previously implicated in thrombus resolution in the rat model of venous 
thrombosis120;121;167;313. Here we aimed to elucidate the temporal changes in a 
wider range of cytokines in the thrombus, vein wall, circulation and laparotomy 
wound associated with HPC mobilisation and recruitment. Cytokines were 






4.1.2 SCA1+CD34+VEGFR2+ (DC101) HPCS AT 12HRS 
Method 
Circulating and BM resident HPCs were measured in three groups of wild type 
Balb/C mice. Ten animals had a thrombus forming procedure, ten had a sham 
operation and 6 animals had no intervention (Sec 2.1.2). Approximately 12hrs 
following thrombus induction all animals were sacrificed under isoflurane 
anaesthetic by exsanguination, blood, thrombus, vein wall, wounds and femur 
bones were collected (Sec 2.1.4). Blood and BM were then processed for flow 
cytometry (Sec 3.2.4 & 3.2.5). HPCs were measured in the mononuclear fraction 
of lysed whole blood and BM and calculated as a percentage of the total number of 
gated mononuclear cells. Any IgG isotype background signal detected was 
subtracted and the three groups were compared in pairs using the Mann Whitney 
U test.  
 
Results  
12hrs post thrombus induction, there was a depletion of circulating HPCs in 
thrombus group mean 0.04% (CI: 0.004-0.09) compared to the sham control group 
mean of 1.92%, (CI: 0.07-3.9, P=0.004, Table 4.1.1, Fig 4.1.1).  
 
The BM resident HPCs also fell from a mean 6.1% (CI:3.2-8.9) to a mean of 1.7% 
(CI:0.75-2.6) in the thrombus group and a mean of 0.95% (CI:0.6-1.3) in the sham 




There was a statistical difference between both operated groups and the non-
interventional group (P<0.05), however there was no difference between the sham 
operated and the thrombus group.  
 
               Table 4.1.1 Percentage of circulating mononuclear HPCs at 12hrs  




Mean 0.503 1.91 0.086 
Standard 
Error 



























  Fig 4.1.1 Circulating HPCs at 12hrs (Mann Whitney U) 
   P>0.05     P= 0.005 






          Table 4.1.2 Percentage of BM mononuclear HPCs at 12hrs   




Mean 6.1 0.95 1.7 

















































4.1.3 CIRCULATING AND BM RESIDENT HPCS FROM 24HRS TO DAY14 
FOLLOWING THROMBOGENESIS 
Method 
Circulating and BM resident HPCs were examined in animals at 24hrs, 48hrs, 7 
days and 14 days. Thrombus was formed in 6 animals at each time point, with an 
equivalent number of sham operated animals (Sec 2.1.2). Blood and BM were 
prepared for flow cytometry (Sec 3.2.4, 3.2.5). Groups were compared in pairs at 
each time point using Mann Whitney U and temporal profiles were compared using 
two-way ANOVA.  
 
Results 
Circulating HPCs  
There was a difference in the temporal circulating profile of HPCs of animals in 
which thrombus had been induced when compared with sham control animals 
(P<0.006, ANOVA). At 24hrs there was a 25-fold increase in circulating SCA-1+, 
CD34+, VEGFR2+ cells above sham controls: 0.378% (CI:0.12-0.76) vs 0.015% 
(0.01-0.13), P=0.004, with a lesser sustained increase between day 7 (P>0.05) and 
14 (P=0.007, Table 4.1.3, Fig 4.1.3).  
 
BM resident HPCs 
There was no difference in the BM resident HPC profiles between those animal in 
which thrombus had been induced and sham controls (P>0.05). BM resident HPCs 




%, CI: 0.03-0.12) when compared with non-operated controls (6.69%, CI: 1.6-9.5, 








































SEM P value 
1 10 0.039  0.033 0.485  0.17 0.006 
2 10 0.114  0.040 0.049 0.011 >0.05 
7 6 0.054  0.034 0.24  0.137 >0.05 



























     Fig 4.1.3 Expression of circulating HPCs day 1-14 
     Thrombus v. sham operated animals (        sham,         thrombus)  















SEM P value 
1 10 1.75  3.60 0.79 2.80 >0.05 
2 10 0.05  2.40 0.07 2.40 >0.05 
7 6 0.43  2.65 0.29 2.67 >0.05 
14 6 0.10  2.55 0.18   2.60 >0.05 
 


























   Fig 4.1.4 Expression of BM resident HPCs day 1-14 
  Thrombus v. sham operated animals (        Sham,        Thrombus),  





   
4.2 CYTOKINE RESPONSE TO VENOUS THROMBOSIS 
4.2.1 AIMS 
A combination of multiplex and sandwich ELISA were used to measure the 
cytokine changes which occurred between 12hrs and day 14 following induction of 
thrombus. GCSF, GMCSF, VEGF, PlGF and SDF1 were measured in mouse 
thrombus, vein wall, plasma and laparotomy wound tissue.  
 
Measurement of cytokines using ELISA 
Method 
All snap frozen tissue specimens underwent protein extraction (Sec 2.1.4). 
Individual sample protein concentrations were then measured using a Bradford 
Assay (Appendix 1). Vein wall and thrombus were aliquoted into 110µl replicates 
for single sandwich ELISA and 200µl replicates which were sent to Perbio® 
laboratories for Multiplex ELISA. GMCSF, VEGF and SDF1 in thrombus, vein wall 
and plasma were all evaluated using the Mulitplex system. PlGF and GCSF were 
analysed as separated sandwich ELISAs. All wound tissue samples were also 
analysed using sandwich ELISA. All results were normalised for protein 
concentration and compared using ANOVA with Bonferroni post-testing. Actual 
protein concentration has not been commented on except for when both thrombus 





4.2.2 GCSF EXPRESSION 
Thrombus expression of GCSF was found to be significantly elevated 12hrs after 
thrombus formation when compared to all other time points (1-way ANOVA, 
P=0.0002) (Table 4.2.1, Fig 4.2.1). Wound GCSF similarly peaked at 12hrs (1-way 
ANOVA, P=0.0001), however wound GCSF protein concentration was 10-fold 
greater than that in the thrombus (Table 4.2.2, Fig 4.2.2). Vein wall expression 
(Table 4.2.3, Fig 4.2.3) of GCSF was significantly greater than sham vein levels of 
the protein at 12hrs but fell to sham vein levels by day 7 (P=0.0047, 2-way 
ANOVA). Data for plasma GCSF was not available owing to limited plasma 
available from mouse blood. 
4.2.3 GMCSF EXPRESSION 
Thrombus expression of GMCSF (Table 4.2.4, Fig 4.2.4) rose significantly by day 
14 (P=0.002, 1-way ANOVA). Comparatively wound GMCSF (Table 4.2.5, Fig 
4.2.5) also peaked at day 14 (P= 0.0047, 1-way ANOVA).  Vein wall GMCSF 
(Table 4.2.6, Fig 4.2.6) was significantly higher than sham levels at 12 and 24hrs 
post thrombus induction falling to sham levels after this point (P=0.004, 2-way 
ANOVA). Plasma GMCSF (Table 4.2.7, Fig 4.2.7) expression in thrombus animals 




4.2.4 VEGF EXPRESSION 
Thrombus VEGF expression (Table 4.2.8, Fig 4.2.8) was maximal 48hrs after 
thrombus formation, producing a bell shaped curve (P=0.016, 1-way ANOVA). 
Wound tissue produced a similar expression pattern (P=0.014, 1-way ANOVA) 
(Table 4.2.9, Fig 4.2.9). Vein wall expression (Table 4.2.10, Fig 4.2.10) were 
statistically higher than the sham expression at 12 and 24hrs, (P=0.0001, 2-way 
ANOVA). Plasma VEGF expression (Table 4.2.11, Fig 4.2.11) was elevated above 
sham levels at only 12hrs (P< 0.05, Mann Whitney U).  
4.2.5 PLGF EXPRESSION 
Thrombus PlGF expression (Table 4.2.12, Fig 4.2.12) peaked at day 7 and was 
falling by day 14, (P=0.0001, 1-way ANOVA). Wound PGF expression (Table 
4.2.13, Fig 4.5.13) did not produce any peaks or troughs like its expression in 
thrombus but produced a constant level of expression which was higher than that 
of thrombus levels until they peaked at day 7. There was bimodal expression of 
PlGF in both the sham and thrombus vein (Table 4.2.14, Fig 4.2.14), the greatest 
expression was at 24hrs, falling by 48hrs and rising again between day 7 and 14. 
Vein wall PlGF expression after thrombus induction remained continuously greater 
than that found in sham vein wall (P=0.0001, 2-way ANOVA). Plasma PlGF 
expression (Table 4.2.15, Fig 4.2.15) was elevated above sham levels at 12 and 





4.2.6 SDF-1 EXPRESSION 
SDF-1 expression in the thrombus (Table 4.2.16, Fig 4.2.16) was significantly 
higher by day 14 than at earlier time points (P=0.0005, 1-way ANOVA). A similar 
pattern was seen in wound tissue P=0.035 (Table 4.2.17, Fig 4.2.17). In the vein 
wall (Table 4.2.18, Fig 4.2.18) there was a bimodal expression pattern which was 
highest at 12hrs in both sham and thrombus operated animals, falling by 24hrs but 
then climbing again only in the thrombus group and remaining elevated above 
sham levels until day 14 (P=0.0036, 2-way ANOVA). There was no statistically 
significant difference between sham or thrombus plasma levels of SDF-1 (Table 































  Fig 4.2.1 Thrombus GCSF expression 
          P=0.0002 (1-way ANOVA) *Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
11.5 1.0 1.0 1.0 1.0 
SEM 
 























  Fig 4.2.2 Wound GCSF expression 
            P=0.0001 (1-way ANOVA) * Bonferroni post test P<0.05 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
362.8 146.7 45.8 61.9 73.7 
SEM 
 





Table 4.2.3 Vein wall GCSF expression  
 
 











      Fig 4.2.3 Vein wall GCSF expression 
                P=0.0047 (2-way ANOVA) *Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  638.0 383.0 189.0 111.0 101.0 
SEM 129.0 98.0 47.0 42.0 27.0 
THROMBUS 
pg/ml 
MEAN 1148.0 632.0 374.0 60.0 144.0 
SEM 116.0 144.0 118.0 12.0 144.0 
   THROMBUS 




















        Fig 4.2.4 Thrombus GMCSF expression 
        P=0.002 (1-way ANOVA) * Bonferroni post test P<0.05 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
0.12 0.047 0.15 0.18 1.3 
SEM 
 





















  Fig 4.2.5 Wound GMCSF expression 
           P=0.0047 (1-way ANOVA) * Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
10.3 9.0 5.2 4.8 14.2 
SEM 
 
4.2 3.7 2.1 1.95 5.9 




Table 4.2.6 Vein wall GMCSF expression  
 
 










    Fig 4.2.6 Vein wall GMCSF expression 
              P=0.004 (2-way ANOVA) * Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  2.2 1.93 1.30 2.35 1.83 
SEM 0.42 0.32 0.39 0.63 0.60 
THROMBUS 
pg/ml 
MEAN 4.8 4.78 3.27 0.83 2.1 







Table 4.2.7 Plasma GMCSF expression  
 
 











  Fig 4.2.7 Plasma GMCSF expression 
           * Mann Whitney P<0.01 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  0.37 0.47 0.40 0.70 0.40 
SEM 0.08 0.1 0.07 0.26 0.13 
THROMBUS 
pg/ml 
MEAN 3.30 0.57 0.50 0.33 0.57 






















           Fig 4.2.8 Thrombus VEGF expression 




TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
3.6 10.6 20.1 1.4 6.9 
SEM 
 






















         Fig 4.2.9 Wound VEGF expression 
         P=0.014 (1-way ANOVA), * Bonferroni post test P<0.05 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
31.6 54.7 62.9 42.6 17.3 
SEM 
 





Table 4.2.10 Vein wall VEGF expression  
 
 
   
 











         Fig 4.2.10 Vein wall VEGF expression 
                   P=0.0001 (2-way ANOVA), * Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  31.9 6.4 5.5 3.8 3.2 
SEM 4.4 0.4 0.9 0.1 0.1 
THROMBUS 
pg/ml 
MEAN 52.8 40.6 22.2 2.9 3.8 
SEM 2.8 1.5 1.9 0.11 0.12 






Table 4.2.11 Plasma VEGF expression  
 
 













        Fig 4.2.11 Plasma VEGF expression  
        P=0.02 (2-way ANOVA), *Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  0.63 0.40 0.40 0.40 0.40 
SEM 0.23 0.00001 0.00001 0.00001 0.00001 
THROMBUS 
pg/ml 
MEAN 2.13 0.40 0.40 0.40 0.40 
SEM 1.1 0.00001 0.00001 0.00001 0.00001 
 *  

























  Fig 4.2.12 Thrombus PlGF expression  
  P=0.0001 (1-way ANOVA), * Bonferroni post testP<0.05 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
1.1 1.8 3.8 197.1 35.4 
SEM 
 
0.2 0.7 0.5 55.5 14.7 





















  Fig 4.2.13 Wound PlGF expression 
  P>0.05 (2-way ANOVA) 
 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 
113.4 98.0 62.1 71.6 69.0 
SEM 
 


















            Fig 4.2.14 Vein wall PLGF expression  
            P= 0.0001(2-way ANOVA),* Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  116.0 108.0 32.0 92.0 81.0 
SEM 24.0 30.0 6.9 18.0 13.0 
THROMBUS 
pg/ml 
MEAN 297.0 310.0 119.0 241.0 197.0 
SEM 52.0 33.0 17.0 25.0 26.0 




















   Fig 4.2.15 Plasma PlGF expression  
             P= 0.004(2-way ANOVA), * Bonferroni post test P<0.05 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  24.5 10 10 10 10 
SEM 12 0 0 0 0 
THROMBUS 
pg/ml 
MEAN 106.5 110 10 10 10 





























      Fig 4.2.16 Thrombus SDF-1 expression 
                P=0.0005 (1-way ANOVA), *Bonferroni post testing P<0.05 























































    Fig 4.2.17 Wound SDF-1expression 
                      P=0.035 (1-way ANOVA), *Bonferroni post test 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
MEAN 
pg/mg 29.8 41.2 41.0 91.6 76.6 
SEM 






















     Fig 4.2.18 Vein wall SDF-1 expression 
               P=0.0036 (2-way ANOVA) 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM  MEAN 648.0 163.0 135.0 218.0 145.0 
SEM 478.0 48.0 19.0 23.0 60.3 
THROMBUS MEAN 631.0 262.0 458.0 357.0 479.0 





















      Fig 4.2.19 Plasma SDF-1 expression 
               P>0.05 (2-way ANOVA) 
TIME   12 hrs   24 hrs  48 hrs 7 days  14 days 
SHAM VEIN 
pg/ml  
MEAN  1408.4 1819.7 1852.0 843.3 1050.2 
SEM 267.6 142.4 262.2 251.1 179.9 
THROMBUS 
pg/ml 
MEAN 845.6 1114.9 1152.0 1348.5 1209.5 






5.0 ENRICHMENT OF CIRCULATING BONE 
MARROW DERIVED MONONUCEAR CELLS ON 
THROMBUS RESOLUTION 
5.1.1 INTRODUCTION 
Studies have demonstrated that enriching the circulation with progenitor cells has 
an effect on a variety of different pathologies such as myocardial infarction and 
lower limb ischaemia383-385. At the time of this study it was suggested that the 
uptake of 3,3,3',3'-tetramethylindocarbocyanine–labelled acetylated LDL (Dil-Ac-
LDL) and binding of Ulex Europaeus Lectin  in combination isolated progenitor 
cells with an endothelial phenotype221;229 . These markers were therefore used for 
our studies in order to assess the mouse spleen and bone marrow for their 
potential to generate progenitor cells for use in interventional studies198;208;209;386;387.   
 
5.1.2 MOUSE SPLEEN PROGENITOR CELL CULTURE  
Aim 









Mouse spleens were removed from Balb/C mice immediately after death, under 
sterile conditions, the spleens were homogenised using a mortar and pestle in PBS 
(on ice). The suspension was filtered through a sterile 70ųm filter (BD Bioscience, 
UK) and the filtrate centrifuged at 600 X g for 10mins (18-20ºC), the supernatant 
was aspirated and the pellet resuspended in 5mls of DMEM (Invitrogen, UK, 37º 
C). The mononuclear fraction of the spleen cells was isolated using a Ficoll density 
gradient (appendix 2). The isolated mononuclear cells were washed with DMEM 
(37º C) and centrifuged at 600 X g for 10mins (18-20°C). The pellet was 
resuspended in Endothelial Basal Medium 2 (EBM-2: Gibco, UK) supplemented 
with 5% fetal calf serum (FCS, Cambrex, UK). Concentrations of two, four or eight 
million cells per ml were placed in 1ml aliquots on a 12 well culture plate (NUNC, 
UK).  
 
The plate had been pre-coated with fibronectin solution 10µg/ml (Sigma, UK). The 
plate was incubated at 37°C and the EBM2 media replenished under sterile 
conditions every 48hrs. Dil-Ac-LDL and Lectin staining was carried out at day 1 
and 7.  
 
Cultured cells were washed with sterile warm PBS and incubated in 2μg/ml 3,3',3'-
tetramethylindocarbocyanine–labelled acetylated LDL (Dil-Ac-LDL, Sigma UK) for 




50μg/ml FITC-labelled Lectin from Ulex Europaeus (Sigma, UK) for 1 hour at 37°C 
in the dark. Cells were ultimately incubated in the blue fluorescent nuclear stain, 
4',6-diamidino-2-phenylindole (DAPI), and viewed under a fluorescent microscope. 
 
Results  
At day 1, spleen cells at all plating densities were phenotypically spherical (Table 
5.1.1, Fig 5.1.1 (a)), and there was no positive staining with DIL-Ac-LDL or Lectin 
(Fig 5.1.1(b)). At day 7 a significant number of spleen cells changed morphology 
becoming elongated and spindle shaped (Table 5.1.1, Fig 5.1.2(a)), as well as 
staining positively for DIL-Ac-LDL and Lectin suggesting a progenitor phenotype 
(Fig 5.1.2(b)).   
 
 
Table 5.1.1 Spleen mononuclear cell generation of progenitor cells  
Time 
(days) 
Sample Dil-Ac-LDL and Lectin staining progenitor cells 
2 million cells/ml 4 million cells/ml 8million cells/ ml 
 
Day 1  
1 -ve -ve -ve 
 
             
2 -ve -ve -ve 
 
Day 7  
1 +ve +ve +ve 
               
             









Fig 5.1.1 Spleen cells in culture on fibronectin 
(a) Spherical mononuclear spleen cells in culture (b) Cells stained with DAPI but no 












Fig 5.1.2 Endothelial lineage cells 
(a) Phenotypically spindle shaped cells in culture between day 7, (b) cells staining 






5.1.3 MOUSE BONE MARROW PROGENITOR CELL CULTURE 
 
Aim  
To grow and characterise progenitor cells derived from the mononuclear fraction of 
mouse bone marrow 
 
Methods 
All steps were carried out a room temperature (18-20°C) unless otherwise 
stated 
 
The femurs of BALB/C mice were removed immediately after death and under 
sterile conditions the BM was flushed from the femur with DMEM (RTP) using a 
30G needle (BD, UK). BM effluent was suspended in 10mls of DMEM solution, pre-
warmed to 37º C. The suspension was filtered through a sterile 70ųm filter (BD, 
UK).The filtrate was centrifuged at 600 X g for 10mins and the pellet resuspended 
in 5mls of DMEM (37º C). The mononuclear fraction of the BM cells were isolated 
using a Ficoll density gradient (appendix 2) and the cells washed with DMEM (37º 
C) and centrifuged at 600 X g for 10mins. The pellet was resuspended in EBM2 
supplemented with 5% FCS at a concentration of 2,4 or 8 million cells per ml. Cells 








At day 1 there were no spindle shaped cells or CFUs seen at any plating density 
(Table 5.1.2, Fig 5.1.3(a)) but  by day 7 at the lower plating densities of 2 and 4 
million cells/ml, CFUs were apparent (Table 5.1.2, Fig 5.1.3 (b) & (c)). CFUs also 
stained positively with the Dil-Ac-LDL and Lectin stains (Fig 5.1.4 (a), (b) & (c)). At 
the higher plating density some spindle shaped cells also co-stained with Dil Ac 
LDL and Lectin. 
 
Table 5.1.2 BMMNC generation of progenitor cells (CFUs) 
Time 
(days) 
Sample Dil-Ac-LDL and Lectin staining colony forming units 
2 million cells/ml 4 million cells/ml 8 million cells/ ml 
 
Day 1  
1 -ve -ve -ve 
 
             
2 -ve -ve -ve 
 
Day 7  
1 +ve  +ve -ve 
               
             














        
        Fig 5.1.3 Bone marrow cells in culture  










        
       Fig 5.1.4 CFUs derived from mouse BM 







5.1.4 EXPANSION OF CFUS FOR USE IN INTERVENTIONAL STUDIES   
 
Aim  
To assess whether BM derived CFUs could undergo passage and expansion in 
vitro, for subsequent interventional studies. 
 
Methods 
CFUs were cultured as described (Sec 5.1.2). At day 7 cells were washed X3 with 
0.9% saline solution and then incubated in one of the following agents: trypsin 
(Serotec, UK), Accutase (Invitrogen, UK) or 1% lignocaine (Pfizer, UK) at the 
recommended concentrations. Incubation in these agents was performed until at 
least 50% of cells had detached from the culture plate. Passaging agents were 
neutralised using 10mls of media (DMEM +5% FCS). Cells were then centrifuged 
at 400 X g for 10mins (18-20°C). All live cells were put back into fibronectin culture. 
 
Results 
Trypsin EDTA produced a cell harvest which was several fold better than the other 
agents tested, however none of the agents used produced CFUs from BMMNCs 























2 44 (1.5) 58,000 (10,000) 0 
Trypsin 2 34 (8.1) 11,000 (3600) 0 
Acutase  2 35 (5) 25,000 (4500) 0 




It was therefore decided that interventional studies would proceed with BMMNCs 
rich in HPCs rather than developed CFU cells which could only be generated in 













5.1.5 LOCALISATION AND IMPACT OF PERIPHERALLY INJECTED BMMNCS 
FOLLOWING THROMBUS FORMATION 
 
Aim 
To evaluate the effect of upregulating circulating BMMNCs on thrombus resolution. 
 
Methods  
Localisation of BMMNCs after tail vein injection 
Thrombus was formed in two groups of four Balb/C mice. At 24hrs following 
thrombus formation, 4 animals underwent tail vein injection of PKH 26 (Invitrogen, 
UK) labelled red fluorescent BMMNCs (Sec 2.4). A further 4 animals were injected 
with carrier solution (DMEM). All injections were carried out with animals under 
anesthetic. At day 2 and day 7 spleen, BM, blood, thrombus and cava were 
harvested. Blood and BM were analysed for the presence of PKH26 red 
fluorescent cells using flow cytometry. Spleen and thrombus were analysed in 
frozen section using fluorescence microscopy (Sec 2.3.3).  
 
Impact of BMMNCs on thrombus resolution  
Thrombus was formed in two groups of 8 Balb/c mice (Sec 2.1.2). After 24 hrs, 
mice were peripherally injected with 250µl of either carrier solution (DMEM) or 1 
million BMMNCs (Sec 2.1.3). At day 7, all animals were culled, thrombus and vein 




Image analysis (Sec 2.3.6) was used to compare vena caval recanalisation in 
control vs. BMMNC injected animals (Mann Whitney U). 
 
Results  
Day 2  
No labelled BMMNCs were identified in the spleen or thrombus.  
 
Day 7 
No labelled BMMNCs were identified in the spleen, a small number of red 







Fig 5.1.4 PKH 26 labelled BMMNCs at thrombus-vein wall interface 
Panel (a) is a DAPI stained cross section of thrombus at X20 magnification, (b) 
X40 magnification of outlined box from (a) showing red fluorescent cell labelling 
 
 b 







Impact of BMMNCs on thrombus resolution  
Injection of the BMMNCs resulted in a doubling of recanalisation, this was a mean 
increase from 5% to 10% (P=0.005, Table 5.1.4). A selection of cross-sections 
taken from control animals and those from animals injected with BMMNCs (Fig 
5.1.6) shows 3 examples of significantly larger recanalisation channels at the 
periphery of the thrombus in those animals injected with BMMNCs. 
 

































Fig 5.1.5 Percentage caval recanalisation  
5% increase in recanalisation following BMMNC injection, 




CONTROL        BMMNC 
     
         
         
 
  Fig 5.1.6 Cross section of thrombi treated with DMEM or BMMNCs  
 (X5 magnification), A (aorta), VC (vena cava), R (recanalisation), T 












6.0 ADENOVIRAL CYTOKINE UPREGULATION  
6.1 ADENOVIRAL TECHNOLOGY 
6.1.1 INTRODUCTION 
Analysis of the cytokine expression in thrombus, vein wall and wound tissues 
suggested that both PlGF and SDF1 may be pivotal to thrombus resolution. PlGF 
produced a unique expression pattern within the thrombus not seen in wound 
tissue and also a bimodal expression pattern within the vein wall. SDF1 also 
produced a bimodal expression in the vein wall and was able to migrate BM 
derived CFU cells in vitro. The expression patterns of these two cytokines within 
the vein wall, mirrored to some extent the expression of the circulating progenitor 
cells. In order to further evaluate this hypothesis the effect of upregulating these 
proteins within the thrombus was assessed using adenovirus technology. Viruses 
have been extensively studied as a method of gene delivery in cancer and 
coronary artery disease388-392. Several types of virus have been used both in the 
laboratory and in clinically based studies, including retroviruses, lentiviruses, 
adenoviruses and adeno-associated viruses391-394. Retroviruses use reverse 
transcriptase to integrate into the host genome, the viruses potential to integrate 
efficiently however requires actively dividing cells, which may not always be 
present395. Adenoviruses such as the ones used here have several features which 
make them ideal for gene therapy studies; they are able to rapidly infect a variety 




in humans396. VEGF has been successfully used to promote thrombus resolution in 
a rat model of thrombosis using an adenovirus313, adenoviral constructs have also 
previously been used to upregulate angiogenic proteins such as SDF-1 and PlGF 
in other models295;321;397. 
Adenoviruses are double stranded DNA icosahedral viruses which will normally 
result in mild coryzal symptoms in the immunocompetent host. The normal 
pathophysiology of this virus results in receptor mediated endocytosis after which 
the virus invades the nucleus, where viral transcription and replication begin398.  
Certain key gene deletions have enhanced the use of adenoviruses both in basic 
and clinical science. Replication defective viruses, known as 1st generation 
adenoviruses have an E1 region deletion and are therefore only able to replicate 
in specifically engineered cells containing the E1 transgene e.g. Human Embryonic 
Kidney (HEK) 293 cells399. Cells infected with replication deficient adenovirus, will 
only produce the experimental transgene for the life span of the virus. The E3 
region encodes for proteins which enable the virus to evade the hosts defence 
system. This deletion also allows the adenovirus to accommodate up to 8kb of 
foreign DNA. Second generation adenoviruses have had further gene deletions 
allowing up to 14kb of foreign DNA to be introduced into the host cell. At the cutting 
edge of adenoviral technology are the third generation or “gutless” viruses which 
are devoid of all viral coding regions400. They are an attractive option for long-term 
transgene expression because of a dampened immune response generated from 








   












6.2 MATERIALS & METHODS 
6.2.1 GROWTH, PURIFICATION AND CHARACTERIZATION OF ADENOVIRUS                    
CONSTRUCTS 
 
The aim of this section of work was to grow and characterise the adenoviral 
construct containing the genes for SDF1; a small quantity of which had been 
donated to the project courtesy of Professor Ron Crystal, Cornell University, New 
York, USA295. The AdPlGF and AdEGFP viruses were acquired from Professor 
Desire Collen’s group at the Department of Molecular and Cellular Medicine, 
University of Leuven. The latter were kindly donated in sufficient quantities for all 
our studies, however titre and function were confirmed prior to use318;319. 
6.2.2 ADSDF1 GROWTH AND CHARACTERISATION 
AdSDF1 is an Ad5-derived E1a-, E3-deficient (E1a-E3-E4-) vector with an 
expression cassette in the E1a region containing the human SDF1 complementary 
DNA (cDNA) and is driven by the cytomegalovirus (CMV) major immediate/early 
promoter/enhancer295. The cassette for the EGFP and the PlGF viruses were 
identical.  
6.2.3 ADSDF GROWTH 
The initial AdSDF1 stock was grown and purified using the Adeno-X Maxi 
purification kit (Clontech, UK). The methodology described below was taken from 





Stage I Growth 
HEK 293 cells were grown to 70% confluence in six 175cm2 cell culture flasks 
(Falcon BD, UK, Sec 2.5, Fig 6.2.1 (A)). The amount of virus added to each flask 
was based on the viral titre. The AdSDF1 was provided at a titre of 1X 109 pfu/ml, 
therefore 5µl of AdSDF1 was added  per 175cm2 of HEK cells, aiming for a 
multiplicity of infection (M.O.I) of 1-2 (if the viral titre is unknown this can be 
calculated using a titre testing experiment, appendix 3). Cells were incubated at 
37°C until the optimal cytopathic effect (CPE) was reached i.e. when 80-90% of 
cells had lifted off the bottom of the plate (Fig 6.2.1 (B)). Cells were placed in a 
sterile 15ml conical tube and pelleted by centrifugation at 1250 x g for 5mins (18-
20°C). The supernatant was discarded and the pellet was resuspended in 5mls of 
DMEM. This suspension was freeze thawed three times in liquid nitrogen and the 
lysate was centrifuged at 1250 x g for 5mins (18-20°C). The supernatant was 
collected and placed in a sterile 15ml conical tube. 5µl of benzonase nuclease (kit 
component) was added and the mixture incubated for 30mins (37ºC), this reduces 
the viscosity of the solution so that it is more easily drawn through the purification 
filter.  An equal volume of 1x dilution buffer (kit component) was added (approx 
5mls) and the lysate was filtered using a 0.45m filter (BD). 
 
Stage II Virus purification 
The virus was purified by selective binding and elution using the kit membrane 




buffer which was drawn into the syringe from the inlet tube and pushed through the 
filter at a rate of 3mls/min (1 drop/sec, Fig 6.2.2).The inlet tube was used to draw 
up the lysate which was also pushed through the filter at a rate of 3mls/min. The 
inlet tube was transferred to a sterile tube containing 20mls of 1X wash buffer 
which was pushed through at a rate of 3mls/min. The purification filter was 
removed from the assembly and the virus was eluted from the filter using 3mls of 
1X elution buffer into a 15ml conical flask. The virus was snap frozen in liquid 















       
            Fig 6.2.1 HEK 293 cells in culture  











Fig 6.2.2 Adenovirus purification filter assembly (Clontech®) 
 
6.2.4 VIRAL TITRE CALCULATION 
The AdSDF1 virus was acquired at a titre of 1X109, following its subsequent growth 
and purification its potency had to be checked to ensure it had not declined. A 
precise titre can be calculated using the Adeno-X Rapid Titre kit (Clontech UK). 
This is a simple antibody based assay that can be used to titre any adenovirus. 
The hexon protein which is encoded by the adenoviral genome, is an essential 
component of the adenoviral capsid required for replication. Its expression is E1 




infected cells will produce the hexon protein. A hexon-specific antibody is then 
used to label infected cells. Counting the number of infected cells per high power 
microscope field can then be used to calculate viral titre after the cells have been 
incubated with varying dilutions of the virus for 48hr incubation.  An overview of the 






















Stage 1) Cell infection 
 
1. A 12 well plate (NUNC, UK) was seeded with 5 x 105  healthy HEK 293 cells 
per 1ml of growth media (DMEM+10% FBS) 
2. Using PBS (pH~7.5) a 10-fold dilution of the AdSDF1 was prepared, starting 
at 10-2 down to 10-6  dilution 
3. 100l of each dilution was added to duplicate wells, leaving one well as a 
control with no virus.   
4. Cells were then incubated for 48hrs in 5% CO2 for 48hrs (NAPCO) 
 
 
Stage 2) Cell staining 
 
1. Cell media was aspirated and the cells dried in a convection hood for 5mins. 
2. Cells were fixed using 1ml of cold (4°C) 100% methanol per well. 
3. The plate was incubated for  20mins at -20°C 
4. The methanol was aspirated. 
5. Cells were washed X3 (PBS + 1% BSA) 
6. Anti-Hexon anitbody (1/1000 dilution) was added to all wells and incubated 
for 1hr (37°C) 
7. Step 5 was repeated.  
8. Rat anti-mouse antibody (HRP conjugate, kit component) was added to 
each well (1/500 dilution) and incubated  for 1hr (37°C) 
9. Step 5 was repeated. 
10. 3 ‘3 Diamenobenzadine (DAB) substrate solution (1/10 with 1X stable 
peroxidise, kit component) was added to each well (500l per well) for 
20mins (20°C). 






Stage 3) Titre Calculation 
 
1. Using a X20 objective lens, stained cells were counted in each field (Fig 
6.2.4), the average of several field was taken to give a more accurate titre.  
 
2. The titre was then calculated using the following formula: 
 
titre = (infected cells /field) x (fields/well) 
 Volume of virus (ml) x dilution factor 
 





















                Fig 6.2.4 DAB substrate stained infected HEK cells  
(A) X20 objective view of infected HEK cells at 10-4 dilution(B) X20 






  Table 6.2.1 Fields to Well ratio as advised by Clontech®  
 
 
6.2.5 REPLICATION COMPETENCY TEST 
10l 1X109 of purified AdSDF1 was added to 1990l serum free DMEM. The media 
from 2 small (25cm2) flasks of human skin fibroblasts (Invitrogen, UK) was 
aspirated, and the diluted virus was added to one flask and serum free DMEM (as 
a control) to the other flask, a third flask of HEK 293 cells was also infected with 
the same viral dilution. Cells were incubated for 2hrs (37°C) and the media 
removed from both flasks and replaced with 10% DMEM. The cells were observed 
over 7-10 days if the virus produced any discernible cytopathic effect on the 
fibroblasts (compare to control cells) then it would have been destroyed (see 
results, Fig 6.3.1).  
 
6.2.6 ELECTROPHORESIS AND WESTERN BLOTTING OF ADSDF-1 PROTEIN 
Gel electrophoresis 
To demonstrate that the AdSDF-1 produced an 8kd protein and a band at the 




(Invitrogen, UK) was used. It comes with precise instructions but the method is 
briefly described below: 
 
The gel cassette was rinsed with deionised water and the sample wells were rinsed 
the with 1X NuPAGE SDS running buffer (Invitrogen, UK).  The X-Cell SureLock 
Mini-Cell electrophoresis system was used (Invitrogen, UK). Supernatant from the 
AdSDF and AdEGFP culture flasks, as well as normal HEK cell media were all 
tested in the reduced and unreduced forms, against a recombinant SDF1 protein 
for comparison. 25µl (max 30µg protein) of sample solutions and protein standards 
((SeeBlue® Plus2 (Invitrogen, UK)) were loaded per well. The gel was run in X1 
MES buffer (Invitrogen, UK) at 200 volts for 35mins at approx. 90amps with an 






Western Blotting  
Proteins were transferred from the NuPage gel to the Hybond PVDF membrane 
using a semi-dry transfer system (BioRad, UK) at 10V for 45mins. (All steps 
performed at 18-20°C).  
 
The gel was first allowed to equilibrate in transfer buffer (5.82g 
Tris(hydroxymethyl)methylamine (BD, UK), 2.9g glycine, 3.75ml 10% sodium 
dodecyl sulphate (SDS) (Gibco, UK), 200ml methanol) made up to 1litre with dH20) 
(pH~9.2) for 1hr (18-20°C). The membrane was soaked in methanol and then 
transfer buffer before it was placed on top of the Hybond-P membrane (GE 
Healthcare), with filter paper on either side (Fig 6.2.5). The process was run at 10V 
for 40mins after which the membrane was placed in block buffer(0.05% Tween20 
(PBST20) with 2% non-fat dry milk (NFDM, Marvel™) for 1hr (18-20°C). The 
membrane was washed X3 with wash buffer (PBST20 and 0.1% NFDM). The 
membrane was then probed with 0.4 µg/ml anti-SDF1 (R & D, UK) antibody diluted 
in wash buffer, it was washed again X3 and the membrane exposed to Streptavidin 
at 1/200 dilution (ELISA kit component, R&D) concentration. Reagents 1 and 2 
from the Enhanced chemiluminescence (ECL™, Amersham) were allowed to come 
to room temperature. Reagents were mixed in equal volume, approx. 0.125 ml/cm2 















Fig 6.2.5 Placement of gel on Hybond PVDF in semi-dry transfer system (Bio 
Rad, UK) 
 
6.2.7 FUNCTIONAL CHARACTERISATION OF ADEONVIRUS PRODUCED 
SDF1 
In order to verify the biological activity of the AdSDF product, a migration assay 
was performed. Using a modified Boyden chamber293 the effect of AdSDF1 
generated protein on BMMNCs and BM derived CFUs was assessed. BMMNCs or 
cultured CFU cells were washed twice with PBS and incubated in a solution of 
DMEM, 2% charcoal treated FBS (foetal bovine serum) and 5mcg/ml of the 
fluorescent marker Calcein (Molecular Probes, UK) for 2 hrs. The cells were 
washed twice with PBS and lifted using 0.25% trypsin EDTA (Serotec, UK). The 
cell suspension was then washed in PBS X2 and resuspended in 1ml of 3.5mg/ml 
BSA in DMEM, at a density of 30X103 per 300µl. 
Lid 
 





3 layers of filter paper 
 





24hrs prior to assay, Falcon HTS Fluroblok (BD, UK) filters were immersed in a 
10% solution of Fibronectin 10mcg/ml (Serotec, UK). The filters were washed with 
DMEM and placed into a 24well plate (BD Falcon). 1ml of either the AdsSDF1 HEK 
supernatant, AdEGFP supernatant test solution was placed in the lower chamber 
and either DMEM or recombinant SDF1 (50µg/ml) were used as controls.  300µl 
aliquots of cells were placed into the top chamber of each well.  Flourescence 
intensity was measured using a (bottom reading) flourimeter (Perkin Elmer), at time 
0, 1hr, 2hrs, 3hrs, 4hrs, 5 hrs and 6hrs, a 2-way ANOVA was used to compare 
migration. 
6.3 RESULTS 
6.3.1 ADSDF1 TITRE 
The AdSDF1 virus was titred at 1X109 pfu/ml. 
6.3.2 REPLICATION COMPETENCY 
After 10 days in culture the fibroblasts showed no evidence of viral cellular infection 













Fig 6.3.1 AdSDF1 replication competency  
(a) Fibroblasts prior to AdSDF1 exposure (b) fibroblasts post AdSDF1 exposure (c) 








6.3.3 ADSDF1 PROTEIN WESTERN BLOTTING 
The reduced supernatant produced a clear band at the same weight as the 
recombinant SDF1 (8kDa). This was not produced by either the control virus 





                
 
          Fig 6.3.2 Western blot of AdSDF1 and AdEGFP supernatant 
          (re: reduced)  
 
  MW kDa    A   B    C     D    E    F    G    H     I     J    
A- marker 
B- SDF standard 
(re) 
C- marker 
D- standard  


























6.3.4 BMMNC AND CFU MIGRATION 
Migration of BMMNCs was unsuccessful (Table 6.3.1, Fig 6.3.3). Both 
recombinant and AdSDF1 generated SDF1 successfully migrated BM generated 
CFU cells at a greater rate than both controls (DMEM and AdEGFP), P<0.0001 
(Table 6.3.2, Fig 6.3.4) 
 
 
Table 6.3.1 Fluorescence value generated by mononuclear cell migration in 




DMEM  SEM AdEGFP  SEM AdSDF-1  SEM 
0 
6534 74 6547 107 7142 6860 
1 
6800 361 7466 902 6669 6930 
2 
7250 86 6885 129 7103 7121 
3 7114 113 7236 251 7835 7867 
4 
9205 644 8220 1046 8498 9159 
5 










































Table 6.3.2 Fluorescence value generated by mononuclear derived 
progenitor cells migration in relation to AdSDF generated protein, AdEGFP 




DMEM  SEM EGFP  SEM AdSDF1  SEM Rec 
SDF1 
SEM 
0 8672 397 8891 140 10790 699 9184 294 
1 9066 589 9796 1063 14697 2451 11760 1826 
2 11993 434 12758 115 22933 3874 17929 3145 
3 14490 889 16239 266 26401 4557 20438 2941 
4 17227 1571 19437 380 30947 5709 23321 3315 









































6.4 PLGF CHARCTERISATION 
6.4.1 ADPLGF 
This AdPlGF virus is also an Ad5 adenovirus, with the same cassette as the 
AdSDF1 and the EGFP virus. As this virus had been donated to the project in a 
fully developed and tested form, only basic testing was performed. The titre of the 
virus was assessed to ensure that the virus was still viable and that its potency had 
not fallen during transit (Sec 6.2.4), its replication competency (Sec 6.2.5) was also 
tested for safety reasons. 
6.4.2 VIRAL TITRE 
The viral titre was confirmed to be 1 X 1011.  
6.4.3 REPLICATION COMPETENCY  
After 10 days in culture the fibroblasts showed no evidence of viral cellular infection 
in comparison to HEK cells which had demonstrated a cytopathic effect at day 3 
(Fig 6.3.1). 
6.4.4 ADEGFP CHARACTERISATION  
The AdEGFP control virus is an Ad5 virus with the same cassette and promoter as 









6.5 IN VIVO CYTOKINE UPREGULATION  
6.5.1 INTRODUCTION 
The final aim of this project was to examine the effect of cytokine upregulation on 
the recanalisation of the vein following thrombosis. The cytokines chosen were 
SDF-1 and PlGF based on their natural profiles during thrombus resolution and 
previously published studies examining their effects on mobilisation of progenitor 
cells in response to tissue hypoxia or injury295;321;404-406. Although viral potency had 
been confirmed   in vitro the ability of the virus to upregulate protein in vivo also 
had to be established. Finally the effect of adenoviral protein upregulation on caval 
recanalisation was assessed using image analysis 
6.5.2 CYTOKINE UPREGULATION USING ADSDF1 AND ADPLGF 
Thrombus was formed in 3 groups of 4 Balb/C mice (Sec 2.1.2). After 24hrs 
animals were re-laparotomized and thrombi were injected with 10µl of either 1X109 
AdPlGF, 1X107 of ADSDF-1 or 1X109 of AdEGFP (Sec 2.1.3). At day 4 following 
adenoviral injection, animals were culled using cardiac puncture, thrombus, vein 
wall and plasma were snap frozen and stored at - 80°C. Tissue samples were 
processed (Sec 2.3.1) and analysed using AdPlGF and AdSDF1 ELISAs (Sec 











Mean SDF-1 levels in thrombus were elevated day 4 post AdSDF-1 injection when 
compared with animals injected with AdEGFP (55.6±6.2 v 31.1±4.4 pg/mg, 
P<0.016, Table 6.5.1, Fig 6.5.1). In the vein wall and the circulation SDF1 levels 
were not significantly different from AdEGFP injected animals (1411±205 v 
1392±302 pg/mg, P>0.05, Table 6.5.2, Fig 6.5.2) and (1230±75 vs 1644±117 
pg/ml, P>0.05, Table 6.5.3., Fig 6.5.3) respectively. 
 
AdPlGF   
At day 4 mean PlGF levels were elevated in all tissues analysed following AdPlGF 
injection when compared with AdEGFP injection; in thrombus (21.1±3.9 v 8.6±0.6 
pg/mg, P<0.05, Table 6.5.4, Fig 6.5.4), the vein wall 243±38 v96±21pg/mg, 
P<0.05, Table 6.5.5, Fig 6.5.5) and the circulation (45.3±21 v 1.2±0.2pg/mg, 
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AdEGFP (n=5) AdSDF1 (n=4) 






























AdEGFP (n=5) AdSDF1 (n=4) 




























AdEGFP (n=5) AdPlGF (n=4) 





























AdEGFP (n=5) AdPlGF (n=4) 

















 Fig 6.5.5 Vein wall PlGF levels day 4 post adenovirus injection 
 
 










AdEGFP (n=5) AdPlGF (n=4) 

















        Fig 6.5.6 Plasma PlGF levels day 4 post adenovirus injection 





6.5.3 THE EFFECT OF SDF-1 & PLGF UPREGULATION ON RECANALISATION 
Method 
Thrombus was formed in 3 groups of ten mice (Sec 2.1.2). After 24hrs animals 
were re-anaesthetized and injected with 10µl of adenovirus into the body of the 
thrombus (Sec 2.1.3). At day 7 following thrombus formation all animals were 
culled using cardiac puncture and tissues harvested (Sec 2.1.4). Thrombus and 
vein wall were processed for paraffin section (Sec 2.3.2). Sections of 5μm were 
taken at 300μm intervals along the entire length of the thrombus. Haematoxylin 
and Eosin staining were performed (Sec 2.3.3) and recanalisation calculated as a 
percentage of total vein wall area was compared between the AdSDF-1 injected 
and AdEGFP injected groups, as well as the ADPlGF and the AdEGFP groups 





AdSDF1 injection resulted in a 5-fold increase in percentage recanalisation 
(P=0.0068, median 2.95%, R=0.7-8.6) v AdEGFP (median 0.62%, R=0.3-4.1, 
Table 6.5.7, Fig 6.5.7), this increased recanalisation however was not associated 
with a corresponding increase in circulating HPCs (P=0.18, median 0.0074%, R= 





The slides shown in (Fig 6.5.11) are representative of the recanalisation observed 
under microscopy.  
 
AdPlGF 
AdPlGF injection resulted in a 6-fold increase in percentage recanalisation 
(P=0.001, median 3.6% R=2.3-4.1) v EGFP control (0.62 %, R=0.3-4.1, Table 
6.5.8, Fig 6.5.8) and was associated with a 6-fold rise in circulating HPCs (P= 
0.028, median 0.0095%, R=0.0001-0.015) v (median 0.0015, R=0.0001-0.015, 
Table 6.5.10, Fig 6.5.10). The slides shown in (Fig 6.5.11) are representative of 



















 Table 6.5.7 Percentage recanalisation at day 7 following injection with 





AdEGFP (n=10) AdSDF (n=10) 




























        Fig 6.5.7 Percentage recanalisation at day 7 following injection with  
        either AdEGFP or AdSDF1 





Table 6.5.8 Percentage recanalisation at day 7 following injection with either 





AdEGFP (n=10) AdPlGF (n=10) 




























Fig 6.5.8 Percentage recanalisation at day 7 following injection with either 
AdEGFP or AdPlGF 





Table 6.5.9 Percentage circulating mononuclear progenitor cells at day 7 
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     Fig 6.5.9 Circulating HPCs at day 7 after AdEGFP or AdSDF injection 
 











AdEGFP (n=10) AdPlGF (n=10) 



























Fig 6.5.10 Circulating HPCs at day 7 after AdEGFP or AdPlGF injection 
 
 






















Fig 6.5.11 Cross sections of 
recanalisation following 
adenoviral injection.  








7.1.1 PROGENITOR CELL EXPRESSION DURING THROMBUS RESOLUTION 
Historically, progenitor cells capable of vasculogenesis were thought only to exist 
during embryological development. It wasn’t until 1997 that Asahara220 first 
provided evidence of what he described as endothelial progenitor cells persisting 
into adult life. The definition of EPCs was based on the presence of two cell 
surface markers; CD34 and VEGFR2220. It is now known however, that using only 
CD34 and VEGFR2 to identify EPCs lacks the specificity required to differentiate 
them from mature endothelial cells221.  The lack of congruity in defining EPCs has 
led to a large volume of literature in which the variable expression of two or more 
markers from CD14, CD31, CD45, CD133, VEGFR2,  vWF  and VE-cadherin have 
all been used to define EPCs325;407. This in turn has made it increasingly difficult to 
compare the results of the numerous studies in this area225;245;382;408-410.  
 
At the inception of this study, it was suggested that CD133 in combination with 
CD34 and VEGFR2 was the gold standard triple label for EPCs227. CD133 is a cell 
surface glycoprotein which was initially thought to exist only in CD34+ progenitors 
found in blood, foetal liver and human BM411. Clinical studies have shown that 
circulating CD133+CD34+VEGFR2+ progenitors correlate inversely with the risk of 
developing cardiovascular disease229;412-414. Although this does not clarify the 





Further evidence for the presence of EPCs in adult life came from Shi et al.415 
when they demonstrated that bone marrow-transplanted CD34+ cells migrated 
onto and covered implanted Dacron grafts and that these cells played a role in new 
vessel formation416. Assessment of the bone marrow transplanted CD34+ cells by 
conventional flow cytometry demonstrated that they were also positive for CD133 
and VEGFR2 but  negative  for CD45, this initially substantiated their identity as 
EPCs and resulted in a deluge of ‘EPC’ research325. Since then however, 
polychromatic flow cytometry has shown that these cells do in fact express CD45 
making them more likely to be derived from a haematopoietic or myeloid lineage417. 
Furthermore in vitro assays of angiogenesis have failed to demonstrate 
conclusively that CD133+CD34+VEGFR2+ cells are capable of giving rise to an 
endothelial phenotype, as they do not form either early or late CFUs or tubular 
structures in Matrigel assays250. Key in vivo studies have also demonstrated that 
following bone marrow transplantation in mice, donor bone marrow cells failed to 
incorporate into blood vessels when assessed by confocal microspcopy (although 
a number of false positive cells were found because of signal overlap). Donor cells 
were however, found in and around the collateral vessels in much greater 
concentration following ischaemic insult251;418. These data suggests that these cells 
may play a pro-angiogenic role as HPCs and not EPCs as once thought225;238. 
 
Having concluded that  the combination of CD34 and VEGFR2 were not sufficient 





on circulating and bone marrow resident Sca1+CD34+VEGFR2+ cells. In this 
project Sca1 was used as a progenitor cell marker (commonly expressed on 
multipotent HSCs223) rather than CD133 which is not found in mice. 
 
Circulating HPCs 
Circulating HPCs in the sham operated animals remained relatively constant 
throughout the experimental period (12hrs-14days); whereas in animals with 
venous thrombosis, there was a sharp early rise in circulating HPC numbers 
followed by a fall and then a later rise that was of a much smaller magnitude. The 
distinct pattern of the changes in circulating HPC numbers compared with those 
seen in sham controls (laparotomy wound healing) suggests an early role for these 
cells during venous thrombosis. Whether their role relates to thrombogenesis or 
early changes associated with thrombus organisation and resolution remains to be 
determined. Similar patterns of progenitor mobilisation are evident in other injury 
models; circulating CD133+VEGFR2+ cells increase by 50% in the first 12hrs 
followed by a rapid fall to baseline within 72hrs in patients who have suffered burns 
or undergone coronary artery bypass grafting247;381. Equally in a myocardial 
infarction study, circulating CD34+ cells peaked at day 7 following ischaemic 
injury381. These results point to an early progenitor response to a variety of 
pathological insults. The literature does not however comment on the subsequent 
secondary rise that occurred in the mouse model following thrombosis or its 





Bone marrow resident HPCs 
There was no significant difference in bone marrow resident HPCs between the 
two intervention groups (sham and thrombus) and HPC levels remained low 
throughout the examined period. At 12hrs however, there is a clear difference 
between animals that have not had any intervention and both the sham and the 
thrombus groups. It must be remembered that the actual changes in circulating 
HPC levels are still a fraction of the much larger change evident within the bone 
marrow compartment. So small differences within this much larger pool of HPCs 
may be difficult to measure, secondly we must consider that cells measured within 
the circulation may have come from alternative progenitor sources such as the as 
liver419. Studies examining bone marrow progenitor populations following vascular 
trauma are rare, one study performed on human subjects following CABG 
demonstrated a reduction in bone marrow CD34 progenitor cells that were CXCR4, 
implying an early role for SDF1420. 
 
7.1.2 THE EFFECT OF HPC UPREGULATION ON THROMBUS RESOLUTION 
The discovery of circulating progenitor cells has lead to a rapid move towards 
interventional studies first in animal models and then in man214;382.  In a hind limb 
ischaemia model in immunodeficient mice, ex vivo expanded human PBMNCs 
were able to recover blood flow compared with animals treated with mature 





Progenitors isolated from cord blood also had a similar effect421. In murine 
myocardial injury models, progenitor cell upregulation reduces myocardial fibrosis 
and preserves cardiac function382. In order to examine the effect of progenitor cells 
on thrombus resolution, an appropriate source of these cells was first identified. 
The circulating volume in mice is too small for use as a source of PBMNCs or 
CFUs. Mononuclear cells derived from both bone-marrow and spleen have the 
ability to generate cells with an endothelial phenotype when cultured using the Hill 
method229 .  In our hands only bone marrow mononuclear cells formed early CFUs 
in culture; a central cluster of cells surrounded by spindle shaped cells at the 
periphery195. Dil-Ac-LDL was taken up by the BMMNC-CFUs which also expressed 
lectin binding221, but consistent with the published literature these cell did not 
express Sca1, CD34 or VEGFR2225.  
 
BMMNC-CFUs similarly to early PBMNC CFUs, do not passage into expanding cell 
lines, suggesting that the BMMNC generated CFUs are similar in nature to early 
PBMNC-CFUs generated by the Hill method 229;422. Lectin binds to endothelial 
cells, HPCs and platelets, with Ac-LDL readily taken up by monocytes and 
endothelial cells 237;238. Proteomic analysis shows that the endothelial cell markers 
(CD31, VWF and lectin binding) found in early peripheral blood CFUs may be the 
result of platelet microparticles which also express these markers, fusing with 
mononuclear cells236. A large number of cells once thought to be EPCs/HPCs are 





Monocytes cultured under angiogenic conditions lose their monocytic lineage 
markers replacing CD14/CD45 with commonly accepted EPC characteristics, 
including LDL uptake, lectin binding and CD31 reactivity425. These cells do not 
incorporate directly into vascular structures but are able to produce several growth 
factors such as GCSF, GMCSF and VEGF, which may be the mechanism through 
which they promote neovascularisation422.  
 
In the present study, systemic injection of isolated BMMNCs rich in 
Sca1+CD34+VEGFR2+ cells following thrombus induction caused a 2-fold 
increase in recanalisation. This is in keeping with data showing that left ventricular 
function and collateral flow are improved in response to transendocardial 
administration of BM or PBMNC cells in a swine model of myocardial 
infarction333;426. In hind limb ischaemia models both intramuscular and systemic 
injection of BMMNCs and PBMNCs result in increased capillary density, muscle 
perfusion and exercise tolerance332;427. Clinical studies have since examined the 
impact of BMMNC or CD133+ cell treatment after myocardial infarction or in critical 
limb ischaemia but the outcomes of these studies have been equivocal328;353;428-430.  
The results achieved in animal models in which young healthy animals are used 
doesn’t always correlate well with the clinical setting in which patients are often 






Several animal models have reported homing of progenitor cells to sites of injury or 
hypoxia194;220;282;432;433, my aim was to examine the post-transplantation location of 
BMMNCs, at 1 and 7 days. Systemic injection of PKH26-labelled cells revealed no 
evidence of cells in the thrombus 1 day after injection but a small number of cells 
were seen in the thrombus vein wall interface by day 7. Less than 0.1% of the 
labelled BMMNCs were detected in thrombus, suggesting that only a small number 
of unselected BMMNCs have the capacity to home to the site of thrombosis. 
Although several studies have examined the impact of BMMNC injection on 
cardiac function434;435, only a limited number have examined bone marrow cell 
engraftment following intra-cardiac or coronary vessel injection436-438. Injection of 
radiolabelled autologous bone marrow mononuclear cells via the coronary artery 
into 10 patients acute or chronic myocardial ischaemia showed that at 2hrs all but 
one patient had evidence of radiolabelled cells could be found in the heart but at 
20hrs BMMNCs were present in the myocardium of only 3 patients (all 3 had acute 
ischaemia)439. The majority of injected labelled bone marrow cells migrated to the 
liver spleen or lung tissues439. The findings in this study are consistency with 
published data in that only a small fraction of bone marrow or progenitor cells 








7.1.3 CYTOKINE EXPRESSION DURING THROMBUS RESOLUTION 
Circulating levels 
Having demonstrated a significant rise in circulating HPCs following thrombosis, 
the possibility that cytokine expression within the thrombus or vein wall preceded 
HPC expression was examined. Cytokine levels (GMCSF, GCSF, VEGF, PlGF and 
SDF1) were measured both in the thrombus, thrombosed and control vein walls 
and the laparotomy wound. The latter was done to elucidate whether wound 
healing and thrombus resolution are orchestrated by similar cytokine expression 
patterns. In this study HPC mobilisation into the circulation was associated with 
early rises in the circulating concentrations of GMCSF, VEGF and PlGF following 
thrombus induction. In animals with thrombus circulating GMCSF was 
approximately 9-fold greater than sham levels at 12hrs, VEGF levels were 3-fold 
greater and PlGF levels were also 3-fold greater but remained at this level until 
24hrs by which time both GMCSF and VEGF and already fallen to sham levels. At 
48hrs following thrombus induction the fall in circulating HPCs coincided with a fall 
in GMCSF, VEGF and PlGF to sham levels. These cytokines are all known to 
affect the mobilisation and recruitment of HPCs301;317;432.  There was however, no 
direct correlation between the numbers of HPCs measured and the circulating 
concentrations of the measured cytokines. Others have found a positive correlation 
between VEGF433  and SDF1441  levels and progenitor cell numbers in the 





The lack of correlation with HPCs in this study may have been the result of low 
sample numbers and hence a type II statistical error.   
 
Vein wall levels 
The levels of GCSF, GMCSF, VEGF and PlGF in the vein walls of animals with 
thrombus were greater than those from sham operated animals. GCSF levels were 
consistently 2-fold greater from 12hrs to 48hrs after which they fell to those of 
sham animals, similar patterns were demonstrated by GMCSF and VEGF. 
Interestingly, although SDF1 is regarded as a cytokine that mobilises bone marrow 
progenitor cells, the concentration of this factor only exceeded sham levels at 
24hrs after thrombus induction but this was not statistically significant on 
Bonferroni post-testing. In the cytokines measured here, only levels of PlGF levels 
remained persistently higher in the vein surrounding thrombus compared with 
same area of vein wall in sham operated animals. Whether this imparts a greater 
importance to the role of PlGF during thrombus resolution is, however, unclear. 
PlGF does appear to be more important in pathological angiogenesis, with loss of 
PlGF resulting in impaired retinal, limb and myocardial revascularisation301;311;444.  
 
Thrombus and wound tissues 
Patterns of cytokine expression in wound tissue and thrombus were similar for 
GCSF, GMCSF, VEGF and SDF1. PlGF expression however, peaked at day 7 





The lack of PlGF upregulation in the wound tissue was not expected and does not 
corroborate the findings of Odoriso445, who demonstrated that PlGF mRNA levels 
peaked at day 2 in a murine wound healing model. One explanation for this may be 
that skin contains hair follicles which are physiologically regulated by PlGF during 
anagen, this may have contributed to overall PlGF expression during cutaneous 
wound healing445. The wound tissue samples used in the present study were 
devoid of dermis and therefore would not be affected by follicular PlGF levels, 
which may account for the discrepancy between these studies. Furthermore it is 
well known that mRNA expression does not always correlate with actual protein 
expression446. 
 
Although there was no direct correlation between thrombus cytokine levels and 
circulating HPCs, cytokines such as VEGF, SDF1 and PlGF have all been 
implicated in the mobilisation and recruitment of progenitor cells into tissues301;447-
449. The complex picture of cytokine expression involved in thrombus resolution 
might suggest that there is a common trigger such hypoxia inducible factor (HIF) 
450. Following venous thrombosis in the mouse, the hypoxic environment within the 
thrombus inversely correlates with HIF1α levels451. Treatment with L-mimosine 
(HIF1 stabiliser) increases HIF1 levels and also results in concomitant increase in 
VEGF and PlGF and the promotion of venous recanalisation and thrombus 
resolution451;452. We speculated that these cytokines in particular PlGF may 





into the thrombus, possibly via the vein wall as previously shown for the 
recruitment of inflammatory cells119.  
7.1.4 PLGF UPREGULATION  
There is evidence supporting the role of PlGF in angiogenesis following a 
pathological insult453. Natural upregulation of PlGF and VEGR1 occurs in hind limb 
and myocardial ischaemia models317;318. In animal models PlGF administration not 
only reverses diminished revascularisation in the ischaemic limbs and myocardium 
of PlGF knockout animals, but also increases neovascularisation in wild type 
animals301.  
 
The unique PlGF profiles found in thrombus and vein wall both suggested that 
PlGF plays an important role in thrombus resolution. Previous studies have shown 
that adenovirus gene constructs (AdVEGF) injected directly into the thrombus, 
transfects cells in the thrombus and local vein wall, with little loss to the liver or 
other organs313;454. To further assess its importance in the venous recanalisation 
we used AdPlGF. Treatment with AdPlGF injected directly into the thrombus after 
induction was associated with an over 40-fold increase in circulating PlGF levels, 
and a doubling in the expression of PlGF in both the thrombus and surrounding 
vein wall. Although there was over a 3-fold increase in vein recanalisation following 
PlGF upregulation, the percentage increase in recanalisation of the vein was small 
(<5%). This small but significant increase in vein recanalisation may, however, be 





thrombotic complications following a DVT455. Greater luminal thrombosis and 
delayed thrombus resolution both result in an increased incidence of post 
thrombotic syndrome456;457. It is therefore reasonable to speculate that smaller 
thrombi and earlier resolution should reduce post thrombotic sequelae. The 
ATTRACT trial is currently randomising patients to either standard treatment with 
anticoagulation versus catheter directed thrombolysis458. This will help to determine 
the long-term benefits of early thrombus removal458.  
 
PlGF is a member of the VEGF family that binds to the tyrosine kinase receptor, 
VEGFR1 (Flt1)301;315. The attributes of VEGF have been heavily explored in both 
animal models and the clinical setting, our understanding of PlGF however, 
remains limited. PlGF and VEGF play a synergistic role in ischaemic angiogenesis 
when compared to the actions of either molecule in isolation301;447. VEGF has three 
receptor subtypes, only one of which (VEGFR1) it shares with PlGF. Although both 
VEGF and PlGF bind to VEGFR1 resulting in its phosphorylation, they induce 
phosphorylation of different tyrosine molecules, suggesting differential actions 
through the same receptor459. Aside from VEGFR1 phosphorylation, several 
mechanisms of action have been suggested for PlGF including displacement of 
VEGF from VEGFR1 allowing increased VEGF-VEGFR2 interaction and 
mobilisation of bone marrow progenitor cells. The data from this study showed that 
plasma PlGF and VEGF peaked early, vein wall levels of PlGF remained 





baseline by day 7. Thrombus VEGF also peaked early at day 2 compared with a 
later peak observed with PlGF at day 7. The prolonged expression of PlGF in the 
vein wall and its late expression in the thrombus suggest that it works 
independently of VEGF in thrombus resolution. PlGF upregulation did however 
upregulate the number of circulating HPCs compared with the AdEGFP (control), 
suggesting a progenitor based mechanism for resolution. In a rat model of venous 
thrombosis the expression of VEGF was similar to that shown in this study167. 
Adenovirus mediated upregulation of VEGF in the rat model resulted in a 4-fold 
increase in venous recanalisation121;313;460.  Although by comparison, the effect 
achieved with PlGF was somewhat disappointing, it is difficult to equate the 
efficacy of PlGF and VEGF treatments in promoting recanalisation in different 
animal models. PlGF treatment has however, resulted in significantly greater 
neovascularisation than VEGF in both coronary  and hind limb ischaemia models in 
mice 317.  
7.1.5 SDF1 UPREGULATION 
SDF1 has been implicated in the migration, proliferation and differentiation of 
several cell types including HPCs and EPCs through its CXCR4 G-protein coupled 
receptor450;461. During natural thrombus resolution SDF1 expression in the 
circulation was not elevated above sham levels, vein wall levels only exceeded 
sham levels after 48hrs and thrombus levels peaked at day 7. Although in the in 
vitro setting CFU cells migrated towards an SDF1 gradient, the latent SDF1 





responsible for the primary HPC response following thrombus formation. 
Interestingly, Upregulation of SDF1 in the thrombus by direct injection of an 
AdSDF1 construct resulted in a 50% increase in thrombus SDF1 without a 
discernible change in circulating or vein wall SDF1. Treatment with AdSDF1 
increased recanalisation by approximately 2-fold and whilst the number of  
circulating Sca1+CD34+VEGFR2+ cells increased above sham levels, this did not 
reach statistical significance. The variability in HPC numbers combined with the 
relatively small number of animals assessed, may have given rise to a type II error.  
 
SDF1 is produced by multiple bone marrow stromal cell types and by epithelial 
cells in many organs462. Thrombus was stained for SDF1 and although we 
demonstrated SDF1 staining in thrombus tissues, this was not associated with any 
specific cell type. In acute coronary syndrome increased platelet bound SDF1 
correlates with circulating CD34+ progenitor cells, platelets may also be the source 
of SDF1 in venous thrombi463. The expression of SDF1 is upregulated during 
ischaemia and this cytokine causes both HPC engraftment and recruitment to 
ischaemic tissue448;462. Neutralising anti-CXCR4 (SDF1 receptor) antibodies 
reduces in vivo homing of myeloid progenitor cells to limb tissue in a hind limb 
ischaemia model464. Upregulation of SDF1 is thought therefore to occur secondary 
to a hypoxic environment449. Oxygen tension in the day 1 murine thrombi is known 
to be significantly lower than that of the normal venous circulation451. In the mouse 





that the trigger in this instance is unlikely to be hypoxia which is no longer present 
by day 14451. 
 
GCSF was the only cytokine to peak in the first 12hrs after thrombus formation and 
to coincide with the low oxygen tension as measured by Evans et al.451. GCSF is 
known to moblise bone marrow resident HPCs and is used clinically for this 
purpose465. GCSF mobilises HPCs through the disruption of the SDF1/CXCR4 axis 
within the bone marrow resulting in an egress of HPCs into the circulation278. There 
is some evidence that GCSF levels correlate more significantly with circulating 
progenitors following tissue ischaemia than other cytokines such SCF, VEGF and 
SDF1466. In the current study the GCSF peak corresponded to the lowest oxygen 
tension measured by Evans et al.451 and preceded the early rise in HPCs. The 
cytokine milieu in upregulating progenitor release is almost certainly complex in 












7.1.6 CURRENT STUDY LIMITATIONS AND FUTURE STUDIES 
 
i. Analysis of progenitor cells and cytokines during natural thrombus 
Resolution 
Phenotyping of circulating cells was hampered by the lack of availability of a multi-
laser flow cytometer. The FACS Calibur® machine used in this study had only a 
single laser, allowing measurement of only three markers for any cell solution. 
Current research into progenitor cell activity in disease is continually faced with 
evolving definitions of what characterises progenitor cells (e.g. EPCs, HPCs or 
MSCs)245;382;409;467. The use of a multiple laser flow cytometer that is able to identify 
12-16 cell markers simultaneously would allow a more refined, simultaneous 
phenotyping of multiple epitopes. This is crucial given that many of the different 
haematopoietic lineage cells can express subtly different surface markers221;225;245.  
 
Although we have demonstrated that venous thrombosis mobilises HPCs, this 
does not show whether there is local HPC engraftment. It is now possible to 
analyse the cell content of tissues such as thrombus using a flowcytometric 
approach. The tissues have to first however, be  enzymatically digested468 and 
care must therefore be taken to validate this technique for the isolation of specific 
cell types, as there is some evidence to show that enzymatic dissolution of tissues 
can modify cell surface markers469. Use of multiple laser flow cytometers would 
result in a more refined and quantitative characterisation of the cells in the tissue 





of cataloguing changes within the various cell populations during thrombus 
resolution and recanalisation120;179;217. Once specific populations have been 
highlighted the onus would then be to determine their functional relevance during 
thrombus resolution. Using both knockout and transgenic animal models, the 
impact of different progenitor phenotypes could be assessed in much the same 
way as monocytes/macrophage heterogeneity has been elucidated470-473.  
 
Lack of access to fluoresence activated cell sorting (FACS) at the time of this study 
also prevented discrete isolation of specific cell populations.  Cell sorting may have 
facilitated the in vitro analysis of cell specific cytokine expression, amongst other 
functional characteristics in a variety of environments including those associated 
with the thrombosis (e.g. low oxygen tension474 or VEGF rich media475). The more 
refined the cell separation technology the more it would facilitate in vivo 
characterisation of the effects of HPCs and other cell types on thrombus resolution. 
One cell population that might prove important in thrombus resolution are 
mesenchymal stem cells, characterised as Sca1+/c-Kit-/Lin-/CD34- cells, they are 
able to form both endothelium and smooth muscle cells and can also generate 
capillary like structures in vitro474. Similarly having produced CFUs from mouse 
bone marrow CFU cells could also be better classified following isolation from non-
CFU forming spindle cells. These cells could then be better analysed with in vitro 






ii. Cytokine analysis and thrombus resolution 
In these studies the mouse model was preferred to the rat model as there was a 
greater availability of antibodies for flow cytometry, ELISA and 
immunohistochemical analysis. The lower volume of plasma and tissue available 
from mice reduced the number of analytes that could be examined and even the 
adoption of a multiplex ELISA system did not fully compensate for this problem. 
For example, the multiplex ELISA system used in this study did not have the 
antibody pairs required for the analysis of GCSF and there was insufficient plasma 
volume to allow the measurement of GCSF using conventional ELISA.  Analysis by 
gene array, although limited to measuring mRNA expression, may allow us to 
develop a more comprehensive ‘picture’ of the temporal changes in the expression 
of genes encoding the whole cytokine family   (and their receptors). Current 
technology in this area is now common place and affordable476.  
A number of cytokines are known to control the recruitment of progenitor cells406. 
Some such as VEGF and SDF1 have been studied in a variety of different animal 
models406. The literature suggests that VEGF and PlGF work synergistically in 
pathological states321;447;453. VEGF has previously been studied in the rat 
thrombosis model and had a greater effect on thrombus resolution than PlGF in the 
current mouse model121;209;313. Studies combining both cytokines would be 






iii. Interventional studies 
Having successfully cultured bone marrow-derived CFUs, they could not be used 
in any interventional studies as the double positive Dil-Ac-LDL lectin labelled cells 
from these cultures could not be adequately passaged. The cell based 
interventional study was therefore carried using the BMMNCs, which contain a 
large variety of undefined progenitor/stem cells, although a significant proportion of 
these cells were Sca1+CD34+VEGFR2+. Only a small number of BMMNCs were 
observed within the body of the thrombus suggesting that the cells important for 
recanalisation represented a very small proportion of the total BMMNC population. 
A flow assisted cell sorter would have allowed isolation and therefore concentration 
of specific cell types more likely to have an effect in the interventional studies. 
 
The AdSDF1 virus had a lesser effect on the circulating HPCs when compared with 
PlGF. It is difficult to compare the efficacies of these constructs as I was unable to 
match the pfu/ MOI used in the treatments as the viral titre for AdSDF1 construct 
(1X109) was lower that achieved for the for the AdPlGF (1X1011). This was despite 
several attempts to grow the construct and the use of different separation 
methods313. It is also difficult to compare the efficacy of the virus constructs as 
some gene products may have a greater potency at lower concentrations477. 
 





(a) Measurement of thrombus weight (that does not provide information regarding 
the area of recanalisation of the vein or the cellular composition /organisation of the 
thrombus). (b) Measurement of thrombus composition and the degree of 
recanalisation by histological means can introduce variability from differences in 
tissue processing and is also costly in terms of animal usage. A method that 
facilitates longitudinal imaging of both physical structure and cellular/molecular 
composition of the thrombus would reduce this variability and dramatically increase 
the power of the analysis of future studies. Over the last decade new imaging 
modalities have become available for use with small animal models have started to 
limit some of these problems. Ultrasound in the form of ‘Photoaccoustics’ allows 
non-invasive real time imaging and is ideal for measuring thrombus volume, it 
would  also allow the measurement of blood flow (vein recanalisation) through the 
thrombosed vessel during the course of resolution. This would enable the 
longitudinal collection of recanalisation data in vivo and reduce the number of mice 
required for analysis478;479. The drawback of this technology is the need for 
expensive micro-bubbles reagents to measure the discrete areas in and around the 
thrombus. Recent advances in micro-computerised tomography (MicroCT) using 
contrast reagents specifically designed for rodent use  have shown that it is 
possible to measure structures down to 20µm in size, this would be invaluable in 







In this work fluorescent labelling of BMMNCs was used in order to monitor their 
recruitment into the vena cava, this again required the use of post mortem 
histological analysis. The migration of progenitor cells once introduced into the 
animal can now be measured by nanotechnology482. Magnetic Resonance Imaging 
(MRI) can be used to track cells with magnetic nanoparticles such as 
superparamagnetic iron oxidase (SPIO) which are internalised by cells to produce 
a magnetic contrast483. Alternatively, positron emission tomography (PET) and 
single-photon emission tomography (SPECT) use radioisotopes with long half lives 
to track cells over hours and days484. 
 
iv) Post-viva amendment 
Following my viva the examiners felt that a further limitation of this study was lack 
of control for inter-observer error. This they felt was particularly relevant to analysis 
of histological sections following intervention. Therefore an acknowledgement of 












7.1.7 SUMMARY  
Thrombus resolution is a complex process that involves tissue remodelling and 
angiogenesis. The cytokine and bone marrow response to DVT may be critical in 
orchestrating these processes485. Venous thrombosis leads to the rapid 
mobilisation of cells expressing haematopoietic markers (Sca1, CD34 and 
VEGFR2), this was associated with an early elevation in circulating cytokine levels. 
The pattern of PlGF expression in the thrombus is different to that in organising 
wound tissue. Upregulating PlGF or the putative progenitor mobilisor SDF1 within 
the thrombus, leads to enhanced venous recanalisation. 
 
A better understanding of the mechanisms that lead to the mobilisation of 
progenitor cells and their recruitment in response to thrombosis, as well as a more 
refined characterisation of these cells should lead to the development of novel 
strategies to promote thrombus resolution. This will be particularly important in 
patients in whom conventional treatments such as anticoagulation or thrombolysis 










(1) Bradford assay  
The Bradford assay is a colorimetric protein assay, which is based on the 
absorbance shift in the dye Coomassie. The red form of the Coomassie reagent 
changes and stabilises into Coomassie blue by the binding of protein. The 
absorbance of the Coomassie blue complex is then read on an absorbance 
plate reader. The (bound) form of the dye has an optimal absorption at 595 nm. 
The increase in absorbance at 595 nm is proportional to the amount of blue 
dye, and thus to the concentration of protein present in the sample. 
 
All steps were carried out at (18-20°C) 
(1) A standard curve using known concentrations of albumin was created using a 
serial dilution method.  80µl of the top standard i.e. 2g of albumin was first 
aliquoted and then 40µl of the top standard was diluted with 40µl of PBS, this 
process was repeated down to a low standard of 0.31 g (Fig A1).  
(2) 10l of solution of interest was placed in duplicate in a 96 well plate (NUNC, 
UK) 
(3) 300l of Coomassie (Thermo Scientific) reagent was then added to each well 





(4) The plate was read in a spectrophotometer (Spectra Max, UK) which calculates 
the protein contents of sample based on the signal generated and compared to 













Fig A1 Serial dilution method used in Bradford Assay 
 
(2) Ficoll density gradient 
The Ficoll-PaqueTM PLUS (Ficoll, Miltenyi Biotec) was mixed thoroughly before use 
by inverting the bottle several times. The Ficoll was then placed in a 15ml conical 
tube (BD, UK). The bone marrow to Ficoll ratio was kept equal i.e. 6mls of Ficoll 
and 6mls of BM cells in (PBS + 10% FCS).  
2g/80l      1g/40l     0.5g/40l      0.25g/40l     
     A     B  C        D   






The BM cells were layered carefully onto the Ficoll to avoid mixing. The tubes were 
balanced and centrifuged (swing bucket rotator) at 400 x g for 30mins (no break, 
18-22°C). This separated the BMMNCs into a single white layer which was 












Fig A2 Ficoll separation of BM cell into mononuclear fraction 
 
 
(3) Optimal Cytopathic Effect (CPE) 
The optimal CPE is reached when the largest number of cells is infected but not 
yet lysed, this occurs when 50% of cells have lifted off the bottom of the well, whilst 
50% are rounded but still attached to the plate.  
 
 
















In order to achieve the optimal CPE the number of virus particles per cell should be 
between one or two times the number of cells in the flask. This is also known as 
multiplicity of infection or MOI.  
 
If the viral titre is known, then the amount of virus added to a flask of HEK cells 
should equate to equal the number of cells in flask in order to achieve an MOI of 
equal to or double the number of cells for an MOI of 2. MOI can be calculated 
using the following formula: 
 
 Vol. of virus required (mls) = number of cells X MOI 
                Viral titre 
 
Therefore if the viral titre is 109 and a 175cm flask contains approximately 1.46 X 
107 cells. In order to achieve an MOI of 1 the amount of virus required can be 
calculated from the following formula: 
 
 
Vol. of virus = 1.46 X 107/ 1 X 109 







If the viral titre is not known then the amount of virus added should be calculated 
by performing a test titre experiment: 
 
1. 3.5 X 105 HEK cells aliquoted into each of the wells of a twelve well plate 
2. various concentrations of virus were then added to each well and the cells 
plate was incubated 
3. the optimum CPE should occur in 2-4 days  
 
Based on this the amount of virus required  for an effective CPE in a 175cm flask is 
roughly equivalent to forty times what is required for a single well of a twelve well 
plate. 
 
4) Inter-observer error  
Following my PhD viva, the examiners concluded that an amendment should be 
put into the Appendix regarding the omission of data pertaining to interobserver 
error. This was in specific reference to the calculation of venous recanalisation in 
the two interventional studies within the thesis; the role of peripheral mononuclear 
cell upregulation in thrombus resolution (Chapter 5) and direct adenoviral 
upregulation in thrombus resolution (Chapter 6). 
 
In this thesis the impact of interventional studies on thrombus resolution was 





highlight areas of thrombus recanalisation which are then subtracted from areas 
containing thrombus. By repeating this at 8-10 levels along each thrombus a mean 
percentage recanalisation and standard error of mean was calculated. The 
observer in this case (myself) was blinded to which slides were from mice that 
underwent treatment or control intervention. Blinding in this fashion aimed to 
remove observer bias in favour of the intervention group, this however does not 
compensate for operators subjective margin of error in measuring the regions of 
recanalisation using the image analysis drawing tool.  
 
Inter observer error 
 
Interobserver error is of significant importance when dealing with subjective 
measurement data. An obvious example of this would be the measurement of 
abdominal organs using ultrasound486. The ability of individual observers to 
independently come to the same conclusion after interpretation of a result is 
described as precision (interobserver agreement) which is not to be confused with 
accuracy. Accuracy in contrast refers to the ability of an investigation or an 
observer to judge something to be a certain way and that that judgment is 
correct487.  
 
There are several approaches to measuring interobserver error; one of the 
simplest indexes of error is the ‘Agreement coefficient’ (percentage). This is 
essentially the number of times the two observers agree on the unit data. This 





find agreement purely by chance and secondly the binary nature of this method 
doesn’t explore varying degrees of agreement. For instance when using ultrasound 
to measure the length of a kidney, one observer may find it to be 11cm, whist 
another observer may measure it to be 10.9cm, strictly this would be counted as 
different but the clinical significance of this difference would likely be minimal.  
 
 A better method is one that accounts for the fact that two observers would agree 
by chance and then measure the relative agreement. This measure of agreement 
is known as Kappa487. It is given as value between 0 and 1, 0 signifying no 
agreement and 1 indicating complete agreement. Although there is no exact cut off 
for what is deemed an adequate value for Kappa, it is suggested that above 0.61 is 
good and above 0.81 is very good488. This value has to be interpreted in light of the 
research area being analysed. 
 
Kappa= (observed agreement-chance agreement)/ (1-chance agreement) 
 
A variation on the Kappa statistic is the ‘weighted kappa statistic’ which also 
engages with the degree of agreement and disagreement. This would be ideal for 
this study where the exact agreement is not sought but degrees of agreement are 
more valuable. 
 
Graphical representation of interobserver error 
 
When graphically displaying interobserver error the Pearson correlation coefficient 





dependent linear relationships, when assessing interobserver error however, it can 
be misleading. An example of this would be two observers measuring the size of 
the abdominal aorta using US, It would be likely that both observers would report 
greater measurements as the size of the aorta increased (i.e. correlation) but the 
actual agreement between the two observers may still be significantly different.  
Another more recently accepted approach to continuous variables is the Bland-
Altman plot489. This was initially used to compare two methods that measured the 
same parameter e.g. computerised tomography and magnetic resonance imaging 
to measure aortic diameter. It can however also be used to assess interobserver 
error. In order to construct the plot, the mean of the two items measured is plotted 
on the x-axis and the difference between the two values on the y-axis. The main 
aim of this graphical representation is to detect bias. This bias might be derived 
from a new technique when compared to the gold standard or bias generated from 
flawed observer technique. In this method if the mean difference moves away from 
zero then the two techniques or observers are not equivalent. The best use of the 
Bland Altman plot appears to be as an adjunct to other more standard graphical 
representations of linear modelling490. It provides additional data allowing the 
reader to judge if either one method can be substituted with another or if data 
collected by one observer agrees with that collected by another. It also allows the 






In this thesis the interventional studies which produced a small but significant 
difference would have been better validated by accounting for Interobserver error. 
There are several techniques as described that might have been utilised here, 
however as the data was only examined by a single observer, this has been 
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